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  I	  
Summary	  
Tumor metastasis requires cell motility driven by actin cytoskeleton dynamics, cell 
adhesion turnover and actomyosin contractility. Regulation of the actin cytoskeleton 
plays a pivotal role in protrusion formation, membrane internalization, force generation 
and intracellular trafficking. Many proteins which affect actin dynamics are found to be 
involved in tumorigenesis and metastasis. Among them, formin proteins as the largest 
group of actin nucleators are emerging to be candidates of drug targets for cancer 
therapy. However, the knowledge of formins in cancer cell invasion is limited. One 
member of the formin family, FMNL2 (formin-like 2), is mutated or upregulated in 
various cancer types.  
In this work, FMNL2 is shown to be phosphorylated by PKCα at the residue Ser 1072. 
Phosphorylation of FMNL2 partially releases autoinhibition leading to higher activity. 
FMNL2-driven cancer cell invasion into 3D matrix is further enhanced by 
phosphorylation of the Ser 1072 residue. In addition, phosphorylation of FMNL2 by 
PKCα results in the internalization of FMNL2 from the plasma membrane through 
endocytic routes. Internalization of FMNL2 is reversible. Mutation of Ser 1072 into Ala 
impedes the rate of internalization. Internalized FMNL2 appears to colocalize with the α5 
integrin positive vesicles, which is consistent with the fact that FMNL2 interacts with the 
cytoplasmic tail of α5 integrin. Furthermore, FMNL2 is required for β1 integrin 
internalization. Together with the fact that actomyosin contractility is reduced when 
FMNL2 is silenced, it is proposed here that FMNL2 drives cancer cell invasion through 
the regulation of integrin trafficking and actomyosin contractility. 
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Zusammenfassung	  
Die Metastasierung maligner Tumore erfordert zelluläre Motilität. Diese wiederum 
beruht im Wesentlichen auf einem dynamischen Umbau des Aktin-Zytoskeletts, einer 
gezielten Modulation adhäsiver Zelleigenschaften sowie der Kontraktilität von Aktin-
Myosin-Filamenten. Eine kontrollierte Umgestaltung des Aktin-Zytoskeletts gilt hierbei 
als Grundvoraussetzung für die Ausbildung zellulärer Protrusionen, dient der 
Generierung von Kraft, ermöglicht eine Internalisierung definierter Bereiche der 
Plasmamembran und besitzt Bedeutung für eine Vielzahl zellulärer Transportprozesse. 
Entsprechend häufig zeigt sich eine Beteiligung Aktin-regulierender Proteine am Prozess 
der Kanzerogenese und Metastasierung. Die Proteinfamilie der Formine bildet die bislang 
größte Gruppe Aktin-regulierender Faktoren und gilt als aussichtsreiche Zielstruktur 
einer pharmakologisch orientierten Tumortherapie. Entsprechend bildet die funktionelle 
Charakterisierung einzelner Formine im Invasionsgeschehen entarteter Zellen einen 
interessanten Gegenstand derzeitiger Forschungsbemühungen, wobei für das Formin 
FMNL2 (formin-like 2) sowohl genetische Mutationen als auch eine gehäuft verstärkte 
Expression in verschiedenen Tumorentitäten nachgewiesen werden konnten. 
Vor diesem Hintergrund gelang im Rahmen der vorliegenden Arbeit der Nachweis einer 
FMNL2-abhängigen Kontraktiliät und Invasivität von Tumorzellen. Als neuartiger 
Mechanismus einer regulierten FMNL2-Aktivität wurde eine PKCα-vermittelte Serin-
Phosphorylierung an Position 1072 charakterisiert. Phosphorylierung von FMNL2 
unterstützt die aktive, nicht/autoinhibierte Konformation des Proteins. Die Expression 
von FMNL2 in Tumorzellen erhöht deren Invasivität in einer dreidimensionalen Matrix. 
Diese Fähigkeit wird durch die Phosphorylierung von Serin 1072 weiter verstärkt. 
Aktivierung von PKCα bedingt eine reversible endozytotische Internalisierung von 
Plasmamembran-gebundenem FMNL2. Interessanterweise zeigt sich derart 
internalisiertes FMNL2 in vesikulären Strukturen, welche ebenfalls den Adäsionsrezeptor 
α5-Integrin beinhalten. Entsprechend kohärent gestaltet sich der Nachweis einer 
physikalischen Assoziation zwischen FMNL2 und dem zytoplasmatischen Proteinanteil 
von α5-Integrin. Darüber hinaus verdeutlicht eine verminderte Internalisierung von β1-
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Integrin in Abwesenheit von FMNL2 die Bedeutung dieses Formins im intrazellulären 
Transportprozess dieser Adhäsionsmoleküle.  
Entsprechend gelang mit der Untersuchung von FMNL2 der erste Nachweis einer 
regulatorischen Phosphorylierung eines Formins durch PKCα. Desweiteren offenbarte die 
Charakterisierung von FMNL2 erstmals die Beteiligung eines Formins an einem 
regulierten intrazellulären Transport des α5β1-Integrin Heterodimers. Somit ergeben sich 
entscheidende Faktoren einer globalen Beeinflussung invasiver Zelleigenschaften durch 
FMNL2 in Form einer ebenso zeitlich wie auch räumlich kontrollierten Beeinflussung 
des Aktin-Zytoskeletts, einer Modulation zellulärer Kontraktilität, ebenso wie einer 
intrazellulären Redirektion von Integrinen. 
	  	  	  	  	  	  	  	  
1	  
1	  Introduction	  
Tumorigenesis requires the interplay of diverse functions in cells including cell survival 
and proliferation, cell motility, cell-cell communication and cell adaptation to the 
microenvironment. Therefore, it is crucial to understand the signal transduction and 
molecular mechanisms of tumor cell motility which enables invasion into surrounding 
tissue, intravasation, transit in the blood or lymph vessels, extravasation and formation of 
colonies at new sites. The motility of eukaryotic cells is regulated by the dynamic actin 
cytoskeleton turnover involved in force generation in membrane protrusion and 
contraction, membrane internalization and intracellular trafficking (Olson and Sahai, 
2008; Pollard and Cooper, 2009). 
1.1	  The	  actin	  cytoskeleton	  
In eukaryotic cells, monomeric actin or globular actin (G-actin) binds ATP/ADP (Figure 
1). G-actin polymerizes into long filaments (F-actin) made of two chains that turn 
gradually around each other to form a right-handed, two-chained long helix (Dominguez 
and Holmes, 2011). ATP hydrolyzes soon after monomers are assembled into the 
filaments but the phosphate dissociation is slow. G-actin always joins the filaments with a 
conformation pointing to the same direction that gives actin filaments an active and 
dynamic barbed end and a less active pointed end (Figure 1). The high amount of actin 
molecules in the cytoplasm is modulated by more than 100 additional proteins to 
maintain an equilibrium at steady state and to initiate reactions in response to signaling 
events. These additional proteins include thymosin-β4 which sequesters actin monomers 
by binding, profilin which inhibits actin nucleation but promotes barbed end elongation, 
capping proteins which block barbed end elongation, crosslinking proteins which make 
networks or bundles and severing proteins which destroy the network or generate free 
barbed ends rapidly available for polymerization (Figure 1) (Pollard, 2007). 
The actin network is responsible for the formation of membrane protrusions at the 
leading edge by pushing the cell membrane. The protrusions, or the so-called pseudopods 
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include the fan-like lamellipodia and finger-like filopodia. These structures of a motile 
cell are important for the directional movement of cells growing on 2D substrates. 
However, for cells cultured in 3D environment or cells growing in the tissue environment 
of a multi-cell organism, the actin network is arranged to support and regulate more 
complicated morphologies including invadopodia and membrane blebs (Nürnberg et al., 
2011). 
 
Figure 1. Actin structure and regulation of polymerization. A. Molecular structure model of 
actin monomer bound to ATP. B. Spontaneous nucleation and elongation. Dimers and trimers are 
unstable. Longer polymers grow rapidly at the barbed end (B) and slowly at the pointed end (P). 
C. Proteins binding to actin monomers. Profilin promotes nucleotide exchange and inhibits 
pointed end elongation. Cofilin inhibits nucleotide exchange and promotes nucleation. Thymosin-
β4 blocks polymerization. D. Reaction of filaments. Capping protein blocks barbed end. Cofilin 
and gesolin sever filaments. Crosslinking proteins crosslink or bundle filaments to generate 
network. Adapted from Pollard and Cooper, 2009. 
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Actin polymerization also contributes to endocytosis (Kaksonen et al., 2006). This 
function of actin is comprehensively studied in budding yeast. Internalization regulates 
the lipid and protein composition of the plasma membrane, which enables cells to adapt 
to changes of the environment. This process depends on the dynamic actin cytoskeleton. 
In addition, the interaction of actin and myosin provides tracks for macromolecules or 
cell organelles trafficking along the actin filaments over short distances (Valdembri et al., 
2009). The generation of contractile forces between actin filaments and myosin is the 
source for cytokinesis in both yeast and mammalian cells.  
1.2	  Regulation	  of	  actin	  nucleation	  
However, nucleation of actin filaments from monomer actin is unfavorable due to the 
extreme instability of small actin oligomers. To overcome this obstacle, cells use 
nucleating factors for de novo actin filament assembly, including the Arp2/3 complex, 
formins, Spire, Cordon-bleu and Leiomodin. The kinetic barrier of spontaneous actin 
assembly and the existence of different nucleating factors provide a platform for spatial 
and temporal control of actin dynamics. Regulation of the nucleators by Rho GTPase 
signaling, second messengers such as phospholipids and posttranslational modifications 
results in coordinated actin nucleation and elongation. 
1.2.1	  Arp2/3	  complex	  and	  branching	  nucleation	  
The first nucleating factor discovered is the Arp2/3 complex (actin-related protein 2/3 
complex) which is composed of seven subunits: Arp2, Arp3 and ARPC1-5. It is 
conserved in almost all eukaryotes (Machesky et al., 1994; Rotty et al., 2013). The 
Arp2/3 complex binds to the side of an existing “mother” actin filament and initiates the 
nucleation and elongation of a new “daughter” filament, resulting in a ~70° branch 
(Figure 2). The binding of Arp2/3 complex to the mother filament involves a 
conformational change that enables Arp2 and Arp3 as a dimer to function as the first two 
subunits of the daughter filament.  
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Arp2/3 complex by itself is not an efficient nucleator. Regulatory proteins called 
nucleation promoting factors (NPFs), actin filaments and an actin monomer are required 
for rapid branching nucleation by Arp2/3 complex (Pollard, 2007). It is also reported that 
phosphorylation of Thr and Tyr residues on Arp2 promotes potent nucleation (LeClaire et 
al., 2008). NPFs are activators of Arp2/3 complex that usually contain three short motifs: 
WH2 (WASP homology 2), connector region and acidic motif. In total it is termed as 
WCA domain. W and C motifs can bind actin monomer while C and A motifs can bind 
Arp2/3. By binding to Arp2/3 complex through WCA domain, NPFs cause a 
conformational change of Arp2/3. The further binding of the large complex to the mother 
filament primes the Arp2/3 complex for nucleation (Figure 2). WCA domain recruits 
actin monomers to Arp2/3 and nucleation continues, after which WCA domain 
dissociates (Goley and Welch, 2006). NPFs include WASP and N-WASP, WAVE/SCAR, 
WASH, WHAMM, JMY and cortactin. Branching nucleation by Arp2/3 complex plays 
crucial roles in membrane protrusion and cell motility, bacteria pathogen movement 
inside the host cell (the formation of the comet tail), and endocytosis (Campellone and 
Welch, 2010; Rotty et al., 2013). 
 
Figure 2. Branching nucleation by Arp2/3 complex. Nucleation promoting factors (NPFs) such 
as WASP bind an actin monomer and Arp2/3 complex. Binding to the side of a filament 
completes activation, and the barbed end of the daughter filament grows from Arp2/3 complex. 
Taken from Pollard and Cooper, 2009. 
1.2.2	  Formins	  and	  the	  WH2	  domain	  containing	  nucleators	  
Formins are homodimers that catalyze the assembly of linear/unbranched actin filaments. 
FH2 (fomin homology 2) domains form donut-shaped head-to-tail dimers that stabilize 
spontaneously formed actin dimers/trimers, thus nucleate actin polymerization (Otomo et 
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al., 2005; Pring et al., 2003). FH2 dimers remain associated with the F-actin barbed end. 
After nucleation, the FH2 dimers move processively along the growing barbed end 
allowing for new actin monomer insertion (see details below). 
The WH2 domain containing proteins, including Spire, Cordon-bleu (Cobl) and 
Leiomodin (Lmod), are recently identified actin nucleators. They employ the WH2 
domain to recruit actin monomers to form polymerization seeds (Chesarone and Goode, 
2009). Spire was found in Drosophila as a factor required for egg and embryonic 
development and was shown to have actin nucleation activity (Quinlan et al., 2005). It is 
suggested later that the Drosophila Spire and the formin protein Cappuccino interact and 
cooperate in actin assembly (Quinlan et al., 2007). The human homologues Spire1 and 
Spire2 also bind FMN1 and FMN2 (Figure 3).  
Cobl nucleates actin into unbranched filaments similar to Spire but with a special 
characteristic that the lengths of the linker between the WH2 domains are crucial (Ahuja 
et al., 2007). Lmod is a muscle specific actin nucleator. It has three actin-binding motifs 
which stabilize actin trimer into a conformation that allows elongation along the barbed 
end (Chereau et al., 2008). Little is known about how Cobl and Lmod are regulated 
(Figure 3).   
 
Figure 3. WH2 domain containing actin nucleators and models for polymerization. Spire 
cooperates with FMN2 to assemble actin filaments. Cobl and Lmod utilize multi actin monomer 
binding motifs to form actin nuclei. W: WH2; L: linker; LRR: Leu-rich repeat; T: tropomyosin 
and actin binding motif; h-b-h: helix-basic-helix. Taken from Campellone and Welch, 2010. 
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1.3	  The	  formin	  family	  proteins	  as	  actin	  nucleators	  
Formins form the largest family of actin nucleators and elongators that assemble 
unbranched actin filaments. They are present in virtually all eukaryotes (Higgs, 2005). 
The first member identified in this family is mouse Formin-1. It was named on the 
hypothesis that a transgene insertion in the limb deformity locus resulted in limb 
formation defects in mice (Woychik et al., 1990). Although later it was found that the 
adjacent gene Gremlin is responsible for limb defects, the name of “formin” remains 
(Faix and Grosse, 2006). There are 15 formin proteins found in human, which are usually 
large polypeptides of more than 1000 amino acids. Phylogenetic analysis of the 
conserved FH2 (formin homology 2) domain reveals that metazoan formins are classified 
into seven subfamilies: Dia (diaphanous), DAAM (dishevelled-associated activator of 
morphogenesis), FMNL (formin-like protein) or FRL (formin-related gene in leukocytes), 
FHOD (formin homology domain-containing protein), INF (inverted formin), FMN 
(formin) and Delphilin (Table 1) (Higgs, 2005).  
Table 1. List of mammalian formins 
 
 
1.3.1	  Actin	  assembly	  by	  formins	  
Formins utilize the FH2 dimers to nucleate and elongate the actin filaments. Exactly how 
formins assemble actin nucleus is unknown. A co-crystal structure of yeast formin Bni1 
Subfamily Members 
Dia mDia1 (DIAPH1) 
mDia2 (DIAPH3) 
mDia3 (DIAPH2) 
DAAM DAAM1 
DAAM2 
FMNL FMNL1 (FRL1) 
FMNL2 (FRL3, FHOD2) 
FMNL3 (FRL2) 
FHOD FHOD1 
FHOD2 (FMNL2) 
FHOD3 
INF INF1 
INF2 
FMN FMN1 
FMN2 
Delphilin Delphilin 
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with tetramethylrhodamine-actin shows that each FH2 dimer binds two actin subunits 
resembling the short-pitch actin dimer of a filament, suggesting that formins stabilize the 
spontaneously assembled actin dimers and trimmers to overcome the kinetic barrier of 
forming tetramers, thus stimulate the polymerization reaction (Figure 4) (Otomo et al., 
2005). Recent studies reveal that in some formins, the region C-terminal to the FH2 
domain might recruit actin monomers to promote nucleation (Chhabra and Higgs, 2006; 
Gould et al., 2011; Heimsath and Higgs, 2012; Moseley et al., 2004; Thompson et al., 
2013).  
 
Figure 4. FH2 dimer structure, FH2-actin complex structure and the elongation model. A. 
FH2 dimer crystal structure of budding yeast formin Bni1. “Lasso” of one FH2 domain extends 
and wraps around the “Post” of the other FH2 domain forming a head-to-tail dimer in a donut 
shape. B. The co-crystal structure of Bni1 FH2 and actin. Space filling model is the actin dimer, 
with FH2 domains wrapped around. C. An elongation model where FH2 dimer adopts a closed (1, 
4) and an open (2, 3) conformation. FH2 dimer associates with the barbed end and FH1 binds and 
recruits profilin-actin to the close vicinity to elongate the filaments. Taken from Campellone and 
Welch, 2010. 
1. Introduction	  
	  	   8	  
The donut shaped FH2 dimers then act as processive caps on elongating filaments 
preventing other capping proteins from terminating the elongation (Zigmond et al., 2003). 
The FH2 dimer has two states on the barbed end: a closed conformation where both FH2 
domains bind the two actin subunits on the end allowing for no insertion of new subunits; 
an open conformation where actin insertion is enabled (Figure 4) (Otomo et al., 2005). 
The rate of elongation is greatly enhanced by the interaction of the adjacent FH1 (formin 
homology 1) domain and the profilin-actin (Kovar et al., 2006; Paul and Pollard, 2008; 
Romero et al., 2004). FH1 domain is rich in proline residues which can bind several 
profilin. The possible mechanism might be that by binding to multiple profilin-actin 
complexes using the “proline-rich track”, FH1 domains increase the local concentration 
of G-actin which can be transferred to the barbed end directly (Vavylonis et al., 2006). 
Although diverse formins share a common mechanism, there exist substantial 
quantitative differences by orders of magnitude in some of the reaction parameters 
(Kovar, 2006; Pollard, 2007). 
1.3.2	  Regulation	  of	  formins	  on	  actin	  assembly	  
1.3.2.1	  Autoinhibition	  
Mammalian formins, especially diaphanous-related formins (DRFs), share a conserved 
domain architecture. A prototypical DRF contains an N terminal regulatory region and a 
C terminal activity region. The N terminus interacts with the C terminus leading to an 
autoinhibition status of the molecule (Figure 5).  The N and C termini interaction is 
mediated through DID (diaphanous inhibitory domain) in the N terminus and DAD 
(diaphanous autoregulatory domain) in the C terminus. Two motifs in the DAD region 
play important roles in the autoinhibition: an amphipathic helix (MDXLLXL, where X 
stands for any amino acids) which is the hydrophobic region contacting a conserved 
surface on DID (Alberts, 2001; Li and Higgs, 2003, 2005), followed by a 3-15 amino 
acid sequence rich in Lys and Arg basic residues which also contributes to the DID-DAD 
interaction (Schönichen et al., 2006; Wallar et al., 2006). The DID-DAD interaction 
inhibits the ability of FH2 domain activity on actin assembly in vitro and in vivo (Seth et 
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al., 2006). It is proposed that the autoinhibition interaction of DID and DAD sterically 
prevents FH2 to contact actin although there is no structural evidence so far. 
 
Figure 5. Diaphanous-related formins are autoregulated by N and C termini interaction. 
GBD: GTPase binding domain; DID: diaphanous inhibitory domain; DD: dimerization domain; 
CC: coiled-coil; FH1: formin homology 1; FH2: formin homology 2; FH3: formin homology 3; 
DAD: diaphanous autoregulatory domain. Adapted from Campellone and Welch, 2010. 
In addition to autoinhibition between the N and C termini, there is a possible inter-FH2 
autoinhibition. Unlike in Bni1 or FMNL3, structural analysis of DAAM1 FH2 dimer 
shows that the FH2 domains are packed together not allowing actin binding thus not 
being able to nucleate actin in vitro (Lu et al., 2007; Yamashita et al., 2007). The novel β-
strand in FH2 linker region leads to the autoinhibition within the FH2 dimer. In fact, 
there are also several formins which are not autoregulated, for example mammalian 
delphilin, FMNL3 and INFs (Chhabra et al., 2009; Miyagi et al., 2002; Vaillant et al., 
2008). How the activities of these formins are controlled is not clear. However it is 
probable that there are binding partners modulating formin activity. One example is Dia-
interating protein DIP. DIP interacts with mDia1 and mDia2, and is required for the 
formation of cortical actin (Eisenmann et al., 2007).   
1.3.2.2	  Activation	  and	  localization	  by	  Rho	  GTPases	  
An enormous amount of research has provided evidences that formin activity and 
localization in cells are modulated by Rho GTPases. Rho GTPases have been 
demonstrated to induce actin stress fiber formation (Rho), lamellipodia formation (Rac, 
Cdc42) and filapodia formation (Cdc42) (Jaffe and Hall, 2005). The function of Rho 
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GTPases on actin remodeling is partially through the largest Rho effector protein family, 
the formins. Extracellular signals stimulate the activation of cell surface receptors and 
signaling factors which recruit and locally activate Rho GTPases. Activated Rho proteins 
bind the GBD domains of the formins thus disrupting the autoregulatory interaction of 
DID and DAD (Rose et al., 2005). In yeast, Rho1 and Cdc42 regulate Bni1 activity. 
Among mammalian formins, Dia, FMNL and DAAM subfamilies are known to interact 
with and be activated by certain Rho GTPases (Young and Copeland, 2010). The active 
Rho proteins also play important roles in plasma membrane localization of formins 
(Block et al., 2012; Chesarone et al., 2010; Seth et al., 2006). 
A consistent effect of Rho activation of mammalian formins is the stimulation of F-actin 
assembly, whereas under different cellular context, the biological functions vary among 
the different formins and Rho GTPases. RhoB localizes to the endosome membranes and 
is associated with both early and late endosome motility. Either mDia1 or mDia2 acts 
downstream of RhoB activation on endosomes. The activated mDia1 or mDia2 stimulates 
actin assembly that impedes or enhances the endosome motility (Fernandez-Borja et al., 
2005; Wallar et al., 2007). FMNL1 is a Cdc42 effector required for phagocytic cup 
formation in macrophages (Seth et al., 2006), while mDia1 acts downstream of RhoA or 
RhoC to induce stress fiber formation (Watanabe et al., 1999). In addition, the FH2 of 
mDia1 is found to be able to activate RhoA through binding to the Rho-GEF LARG, 
which suggests a positive feedback loop between formins and Rho GTPases (Kitzing et 
al., 2007; Shi et al., 2009). 
However, in vitro pyrenyl-actin assays show that to disrupt the DID-DAD interaction 
between the N and C termini of formin mDia1 or FMNL1 requires much higher 
concentration of RhoA or Cdc42 protein than the N or C terminus proteins (Brandt et al., 
2007; Seth et al., 2006). This indicates that additional factors other than active Rho 
GTPases are involved in the activation process in the cells. One possibility is the 
involvement of another interacting protein. Indeed, the DAD of DAAM1 binds 
Dishevelled (DVL) and this interaction either acts independently or together with Rho 
protein to fully activate DAAM1 in response to non canonical Wnt signaling (Liu et al., 
2008).  
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1.3.2.3	   Activation	   and	   localization	   by	   post-­‐/co-­‐translational	   modification	   and	   other	  
factors	  
Release of autoinhibition can also be accomplished by post-translational modifications. 
During budding yeast mating, a pheromone-activated MAP kinase Fus3 phosphorylates 
Bni1 in vitro, and phosphorylation of Bni1 in vivo during the pheromone response is 
dependent on Fus3. Activated Fus3 is recruited to the cortex, where it activates Bni1 to 
assemble cortical actin cable and promote polarization and cell fusion (Matheos et al., 
2004). Prk1 (p53-regulating kinase 1) also phosphorylates Bni1 and releases the 
autoinhibition thus mediating actin assembly involved in exocytosis and endocytosis of 
budding yeast (Wang et al., 2009). Mammalian FHOD1 is phosphorylated by ROCK 
(Rho associated coiled coil containing protein kinase) at three conserved residues in the 
polybasic region after DAD domain which is sufficient to disrupt the autoinhibition of 
FHOD1 to form stress fibers (Takeya et al., 2008). FHOD1 was also shown to physically 
interact with ROCK and induce plasma membrane blebs depending on Src and ROCK 
activity (Hannemann et al., 2008). Moreover, INF2 is farnesylated, which targets it to 
endoplasmic reticulum membranes possibly independent of Rho and enables INF2 to 
assemble actin locally needed for mitochondria fission (Chhabra et al., 2009; Korobova et 
al., 2013). 
The FMNL formin subfamily is found to be co-translationally N-terminally myristoylated 
which regulates the localization of FMNL formins to the plasma membrane (Block et al., 
2012; Han et al., 2009; Moriya et al., 2012). FMNL1γ, an isoform of FMNL1, is located 
at the cell membrane and cortex in diverse cell lines depending on myristoylation of Gly 
at the second position of the polypeptide. This isoform induces non-apoptotic membrane 
blebs independent of Src or ROCK activity (Han et al., 2009). Another study has reported 
that FMNL1γ regulates cellular F-actin levels required for maintaining structural integrity 
of the Golgi complex and lysosomes (Colón-Franco et al., 2011). FMNL2 and FMNL3 
localization to the plasma membrane is also abolished if the second Gly is mutated into 
Ala. Block et al. have reported that FMNL2 localization depends on both N-
myristoylation and Rho GTPases (Block et al., 2012). A previous report has pointed out 
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that FMNL2 drives rounded cell invasion in 3D downstream of RhoC (Kitzing et al., 
2010).   
As mentioned above, proper formin localization is not always completely disturbed by 
inhibition of Rho GTPases. The dimerization and coiled-coil domains of mDia1 can help 
direct the localization (Copeland et al., 2007). IQGAP binds to the FH3 of mDia1 and is 
required for mDia1 localization to the phagocytic cup (Brandt et al., 2007). The spatially 
controlled localization and activation of formins guarantee that they regulate actin 
assembly locally.  
1.3.3	  Cellular	  functions	  of	  formins	  
Formins mediate actin polymerization in the formation of a substantial variety of cell 
structures. In fission yeast cytokinesis, Rho activity is accumulated around the equator of 
the cell (Miller and Bement, 2009). Myosins capture actin filaments assembled by 
formins around the equator and pull the actin filaments into a contractile ring (Vavylonis 
et al., 2008). mDia2 is also found to induce F-actin forming a scaffold for the contractile 
ring and maintain its position in the middle of a dividing cell (Watanabe et al., 2008). 
Multiple DRFs also nucleate actin at filopodia or lammelipodia tips where they contribute 
to cell motility (Harris et al., 2010; Pellegrin and Mellor, 2005; Peng et al., 2003; Yang et 
al., 2007).  
Actin polymerization triggered by the FH2 domains of formins is linked to the serum 
response factor (SRF) controlled transcription. G-actin can bind the myocardin-related 
SRF cofactor (MAL) in the N-terminal RPEL motifs, which inhibits MAL translocation 
from the cytoplasm into the nucleus. Formins, such as Dia, DAAM, FMNL and INF, 
employ large amount of G-actin to assemble F-actin so that MAL is released and able to 
enter the nucleus (Copeland and Treisman, 2002; Copeland et al., 2007; Grosse et al., 
2003; Hill et al., 1995; Kitzing et al., 2010; Miralles et al., 2003; Sotiropoulos et al., 
1999). As the transcriptional coactivator, MAL together with SRF starts an array of gene 
expression including 29 genes encoding cytoskeletal or contractile proteins (Baarlink et 
al., 2010; Faix and Grosse, 2006; Young and Copeland, 2010). Therefore, formins 
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contribute to the gene expression involved in cell migration, contractility and 
morphogenesis through serum response factor (Figure 6). Apart from that, G-actin is 
known to shuttle between the cytoplasm and the nucleus (Pederson and Aebi, 2002) while 
a number of formins have been shown to have nuclear localization signals (Chan and 
Leder, 1996; Copeland et al., 2007; Johnston et al., 2006). A very recent study has indeed 
identified that serum stimulation induces nuclear actin assembly depending on activated 
mDia1 and mDia2 in the nucleus. Formins polymerizing actin inside the nucleus drives 
serum-dependent MAL/SRF activity, suggesting a role of formins in the formation of the 
nucleoskeleton and a regulatory mechanism in transcription (Baarlink et al., 2013). 
 
Figure 6. Representative scheme of MAL/SRF 
transcriptional activation by the formin mDia1. A 
pool of cytoplasmic G-actin binds to MAL which 
prevents MAL translocation into nucleus. Upon 
mDia1 activation by RhoA, G-actin molecules are 
utilized by the formin to polymerize F-actin. The 
conformational change of G-actin during assembly 
into F-actin releases MAL. MAL accumulates 
rapidly into nucleus, which in turn drives MAL/SRF-
dependent gene transcription including genes 
involved in cytoskeletal dynamics, adhesion and cell 
shape. This is likely to form a feedback loop in 
response to the actin turnover in the cytoplasm. 
 
1.4	  Cancer	  cell	  invasion	  
Cancer cells spreading from the original tumor and the subsequent growth in new sites of 
the body is the most life-threatening disease which is called metastasis. This complicated 
process requires cancer cells responding to signaling cascades to survive, proliferate, 
move through the tissues surrounding the tumor, penetrate the basement membranes and 
endothelial walls into vasculature and disseminate to finally colonize in distant organs 
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(Figure 7) (Friedl and Alexander, 2011; Sahai, 2007). One of the crucial steps of 
acquiring invasive ability is the deregulation of signaling pathways leading to changes of 
gene expression and function that modulate the actin cytoskeleton dynamics. Alteration 
of actin cytoskeleton affects cell-cell contacts, cell adhesion and membrane protrusion 
which are all fundamental structures controlling cell motility. The pathways regulating 
actin dynamics may also affect growth control and cell survival (Olson and Sahai, 2008).  
 
Figure 7. The metastatic process. Primary tumor cells invade in the tissue environment, 
disseminate and intravasate into blood or lymph vessels. These cells transit in blood stream, 
attach, extravasate and colonize in a new site. Taken from Sahai, 2007. 
1.4.1	  Modes	  of	  cancer	  cell	  invasion	  
To understand how cancer cells move, an enormous amount of researches have been 
performed using 2D or 3D in vitro models, consisting of random or directed cell 
movement on 2D substrate and cell invasion towards chemo-attractants through a barrier 
into 3D matrix, both in combination with time-lapse or conventional microscopy methods. 
The development of two-photon or multi-photon intravital imaging has provided insights 
into the tumor cell motility in living mouse models (Friedl and Wolf, 2003; Sahai, 2007). 
The combination of in vivo and in vitro research models reveals that cancer cells use 
different invasion patterns which can be roughly classified into mesenchymal motility, 
amoeboid/rounded motility and collective motility (Figure 8). 
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The mesenchymal mode of cell motility is so far the best understood mechanism of cell 
migration in either 2D or 3D environment. Cancer cells undergo epithelial to 
mesenchymal transition (EMT) due to the sustained change of oncogenic gene expression 
(Thiery, 2002). Mesenchymal motility is characterized by an elongated cell morphology 
with an established polarity and is dependent on focal adhesion turnover, actomyosin 
contractility and proteolysis of the extracellular matrix (ECM). Cells using the 
mesenchymal mode of motility move relatively slow (0.1-1 µm/min) (Friedl and Wolf, 
2003). The signal transduction through cell surface receptors initiates the activation of 
Rac and production of phosphatidylinositol-3, 4, 5-triphosphate (PIP3) which are known 
to activate WAVE and subsequently the Arp2/3 complex. The Arp2/3 complex regulates 
spatiotemporal actin assembly that drives the protrusion of pseudopods at the leading 
edge of the cell. Cdc42 and PI3K (phosphatidylinositol-4, 5-bisphosphate 3-kinase) are 
also activated to promote actin polymerization (Pollard and Borisy, 2003; Ridley et al., 
2003). As the new protrusion of cells gets into contact with the ECM, cell starts the 
formation of small dynamic focal contacts through integrins and other receptors on the 
membrane. The adhesion molecules lead to the accumulation of surface proteases, such 
as membrane-type matrix metalloproteinases (MT-MMPs), which degrade the ECM 
providing space for the cells to crawl (Wolf et al., 2007). Some focal contacts develop 
into large focal adhesions that enable the actomyosin contractility regulated by Rho and 
ROCK activity to be transmitted to the ECM, facilitating cell body to follow the leading 
edge and retract the cell rear (Figure 8) (Sahai and Marshall, 2003). Mesechymal tumor 
cells usually come from tumors of connective tissue (Friedl and Alexander, 2011).  
Intravital imaging approaches have demonstrated that some cancer cells in the tumor 
body can move like the single-cell amoeba Dictyostelium in an amorphous or round 
shape and at a relatively high speed (0.1-20 µm/min). This kind of cell movement is 
named as amoeboid or rounded motility (Friedl and Wolf, 2003). Amoeboid movement 
may employ Rac-dependent filopodia and has small or loosely organized adhesion sites. 
Cells have weak adhesion forces, no stress fibers, and lack proteolysis of the ECM 
(Lämmermann and Sixt, 2009). The second form of amoeboid movement uses Rho-
ROCK dependent cortical actomyosin contractile forces to remodel the cell shape (Olson 
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and Sahai, 2008). Chemoattractant activates the membrane receptors triggering actin 
polymerization leading to the formation of a pseudopod. Rho-ROCK dependent 
contractile force in cortical actin generates hydrostatic pressure that reshapes the 
membrane. Amoeboid tumor cells exhibit low levels of β1 and β3 integrins, forming low 
levels of adhesion with collagen substrates (Friedl and Wolf, 2003; Hegerfeldt et al., 
2002). Under the guidance of the chemoattractant, cells squeeze forward through the 
ECM with little or no focal contacts and cells move independently of extracellular 
proteolysis (Figure 8) (Sabeh et al., 2009). Amoeboid tumor cells usually originate from 
leukemia, lymphoma and small cell lung carcinoma (Friedl and Alexander, 2011). The 
rounded movement is also detected in other tumor cell types such as melanoma cells 
(Sanz-Moreno et al., 2008). 
 
Figure 8. Mechanisms of cancer cell motility. Mesenchymal motility is characterized by an 
elongated morphology and ECM degradation. Amoeboid motility is defined by an amorphous 
morphology and dependent on actomyosin contractile force to reshape the cells while squeezing 
through the ECM. Collective motility retains cell-cell junctions and is characterized by the 
movement of a collection of cells. Adapted from Sahai, 2005. 
Collective motility requires intact cell-cell junction, proteolytic activity and multicellular 
coordination during simultaneous migration. In most cases of collective invasion, cells 
move simultaneously with a mechanism similar to a collective form of mesenchymal 
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motility. Leading cells in the front respond to the chemoattractants, form protrusions, and 
degrade the ECM generating a “path” for the following cells to move through (Figure 8) 
(Gaggioli et al., 2007; Sahai, 2005). Collective motility resembles the cell movement of 
morphogenesis during development. Collective migrating tumor cells are found in most 
epithelial and mesenchymal tumor types (Friedl and Gilmour, 2009). However, collective 
invasion is poorly studied due to the difficulties in setting up a model system in vitro. 
1.4.2	   Switching	   between	   the	   modes	   of	   invasion	   and	   the	   plasticity	   of	   tumor	  
invasion	  
Inhibition of the proteases required for mesenchymal motility fails to stop cancer cell 
invasion but leads to the switch to amoeboid motility (Wolf et al., 2003). Blocking β1 
integrin with antibody results in the switch from collective invasion into amoeboid 
invasion that does not require adhesion to the ECM (Hegerfeldt et al., 2002). Constriction 
of the cortical actomyosin enables cells not only to squeeze themselves through the ECM 
but to remodel the ECM to create invading tracts (Sanz-Moreno et al., 2011; Wyckoff et 
al., 2006). All the evidences imply that there exists a high degree of plasticity in cancer 
cell invasion. In particular, it has been reported that Rac activation and inactivation 
control the plasticity of melanoma cells to adopt mesenchymal or amoeboid motility 
(Sanz-Moreno et al., 2008). In mesenchymal movement, activation of Rac through a 
complex containing NEDD9 and the Rac-GEF DOCK3 leads to the actin assembly via 
WAVE2-Arp2/3 pathway directing the elongated movement. Amoeboid motility is 
decreased via decreasing actomyosin contractility. Whereas in amoeboid movement, 
ROCK signaling inactivates Rac through activating the Rac-GAP ARHGAP22, thus 
suppressing the elongated motility. This study reveals the molecular mechanism of how 
cancer cells switch between modes of motility. Furthermore, tumor cells moving through 
all the obstacles to invade require various actin cytoskeleton organizations. The versatile 
nucleating, elongating, capping, severing, crosslinking factors that regulate the actin 
assembly also provide a flexible platform of cytoskeleton reorganization favorable during 
migration and invasion. In N-WASP and WAVE2 depleted cells, mDia1 acts downstream 
of RhoA to form jagged protrusions with lamellar properties and to increase filopodia 
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formation, indicating a crosstalk and compensatory mechanism between the two groups 
of actin nucleators in membrane protrusion formation required for cell motility 
(Sarmiento et al., 2008). Therefore, the plasticity of switching the tumor invasion modes 
and the diverse actin cytoskeleton regulation are challenges for researchers to develop 
cancer therapies. 
1.4.3	  Formin	  proteins	  in	  invasive	  diseases	  
The expression and activation of Rho family proteins have been extensively studied in 
cancer cell migration and invasion (Ellenbroek and Collard, 2007). As Rho effectors, 
formins are gradually recognized as potential candidates for anti-invasive drug targets.  
Among all the formin proteins, mDia1 has been implicated in a variety of processes 
promoting cell adhesion and migration. The Rho-mDia1 pathway is implicated in Src-
mediated remodeling of focal adhesions and migration of glioma cells (DeWard et al., 
2010; Narumiya et al., 2009). In 3D invasion model studies, mDia1 is required for 
invasive cancer cell migration as well as invadopodia formation (Kitzing et al., 2007; 
Lizárraga et al., 2009). Another evidence for mDia1 in invadopodia formation and 
invasion is that mDia1 targets v-Src to the cell periphery and facilitates v-Src induced 
transformation. Depletion of mDia1 in v-Src transduced cells leads to the failure of these 
cells invading or forming tumors in nude mice (Tanji et al., 2010). Like mDia1, mDia2 is 
also implicated in invadopodia formation and invasion (Lizárraga et al., 2009). Moreover, 
depletion of mDia2 in prostate cancer cells enhanced plasma membrane blebbing upon 
EGF stimulation and increased metastasis, suggesting an interesting suppressive role of 
mDia2 in tumor progression (Hager et al., 2012; Vizio et al., 2009). Other formin 
proteins also play a role in bleb-associated cancer cell invasion such as FHOD1 and 
FMNL1 (Han et al., 2009; Hannemann et al., 2008) although the precise underlying 
mechanisms remain unclear.  
Sequence analysis of cancer genomes from glioblastoma or pancreatic cancer patients has 
identified missense mutations in FMNL2 and FMNL3 (Jones et al., 2008; Parsons et al., 
2008), while the functions of these mutations are not yet defined. However, FMNL2 was 
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found to be upregulated in colorectal cancer and in cell lines derived from colorectal 
cancer metastasis (Zhu et al., 2008). Studies from the same group later found that 
FMNL2 enhanced TGFβ-induced EMT and promoted colorectal carcinoma cell invasion 
and metastasis (Li et al., 2010; Zhu et al., 2011). They also identified that FMNL2 was 
targeted by micro RNA inhibiting signaling of PI3K, PKB/Akt (protein kinase B) and 
MAPK (mitogen-actiavted protein kinase) to reduce colorectal cancer invasion (Liang et 
al., 2013). Additionally, in a systematic screen of effects of human formins on cancer cell 
invasion, FMNL2 was identified as an important factor driving the amoeboid/rounded 
mode of invasion downstream of RhoC (Kitzing et al., 2010). Whether RhoC and 
FMNL2 or other factors play a role in invasion and metastasis in vivo would be 
interesting to investigate. 
1.5	  Protein	  kinase	  C	  and	  its	  role	  in	  invasion	  and	  metastasis	  
Protein kinase C (PKC) was identified by Nishizuka and colleagues as kinases that are 
activated by proteolysis (Takai et al., 1977). Diacylglycerol (DAG) was soon found to be 
the natural activator of the intact enzyme (Takai et al., 1979). PKC caught the attention of 
cancer researchers in the early 1980s after it had been identified as the target of the 
phorbol esters which have tumor promoting activity (Castagna et al., 1982; Kikkawa et 
al., 1983; Leach et al., 1983; Mochly-Rosen et al., 2012). This important discovery 
attracted researchers over years to develop drugs targeting PKC in cancer and other 
diseases. The identification of nine PKC genes encoding at least ten PKC isozymes 
complicates this research field. These isozymes are highly homologous and can be 
classified into three groups according to different activation mechanism: classical PKCs 
(cPKCs: PKCα, PKCβI, PKCβII, PKCγ), novel PKCs (nPKCs: PKCδ, PKCε, PKCη, 
PKCθ) and atypical PKCs (aPKCs: PKCζ, PKCλ/ι). cPKCs are activated by calcium and 
DAG. nPKCs are activated only by DAG, whereas aPKCs are not responsive to either 
calcium or DAG (Griner and Kazanietz, 2007). PKCα, PKCδ and PKCε are ubiquitously 
expressed while other PKCs are more cell-type specific. PKC is able to phosphorylate 
large number of substrates at their Ser/Thr residues. Therefore, PKC regulates a broad 
range of cellular events.  
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Figure 9. Domain structure of PKCs. Upper: all PKCs have a regulatory domain containing C1, 
C2 regions and a pseudosubstrate (PS) region (in green). C1 binds phorbol esters or DAG. C2 
binds calcium. C2 of nPKCs does not bind calcium. C1 of aPKCs does not bind DAG. Kinase 
domains are more conserved among PKCs than regulatory domains. PKC isoform variable 
regions are shown in gray. PB1 (Phox and Bem 1) of aPKCs interacts with other proteins. Lower: 
structures of C1, C2 and kinase core. Adapted from Steinberg, 2008.  
1.5.1	  Structure	  and	  activation	  of	  protein	  kinase	  C	  	  
PKC contains a regulatory domain in the N terminus and a kinase domain in the C 
terminus (Figure 9) (Steinberg, 2008). In the inactive state, the regulatory domain binds 
to the kinase domain inhibiting the catalytic activity of the kinase. Upon stimulation of 
the receptor tyrosine kinase or the G-protein coupled receptor, phospholipase C (PLC) 
cleaves phosphatidylinositol-4, 5-biphosphate (PIP2) into soluble second messenger 
inositol triphosphate (IP3) and the membrane lipid DAG. IP3 releases calcium from the 
endoplasmic reticulum. Calcium binds to the C2 region of the regulatory domain which 
pre-targets the cPKCs to membranes. DAG binding to the C1 region of the regulatory 
domain further promotes the membrane-binding affinity of PKC. Subsequently a massive 
conformational change happens to release the pseudosubstrate domain from the substrate-
binding site allowing for substrate binding and phosphorylation of the downstream 
effectors. In the activation process, receptor of activated C-kinase (RACK) acts as the 
anchoring protein for PKCs (Figure 10). nPKCs lack calcium binding sites but have an 
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increased affinity for DAG as a compensation (Griner and Kazanietz, 2007; Parekh et al., 
2000). In addition, to undergo trans- and auto-phosphorylation on themselves is a pre-
requisition for the maturation, activation and stability of PKCs. Of note, in response to 
the stimulation of receptors or phorbol esters, PKCs can translocate from cytosol to the 
plasma membrane, nuclear membrane, Golgi apparatus, mitochondria or other organelles, 
implying a specific mechanism of local activation of downstream events (Garcia-Bermejo 
et al., 2002; Wang et al., 1999). The redistribution to different organelles might relate to 
PKC binding to specific lipids or proteins (Jaken and Parker, 2000).  
1.5.2	  Protein	  kinase	  C	  in	  invasion	  and	  metastasis	  
Much of the work on PKC function was performed with phorbol esters which are 
irreversible. DAG stimulation in cells is only transient. It is also known that there exist 
far more DAG effectors than only PKCs. Nevertheless, PKCs have been implicated to 
play important roles in cell proliferation and cell death, gene transcription and translation, 
cell motility, cell-cell contacts, regulation of receptors and channels, endocytosis and so 
on. More efforts are required to identify the functions of each isozymes in disease 
progression using isozyme specific pharmacological drugs or other approaches.  
 
Figure 10. Activation of classical PKCs. Upon 
stimulation, PLC cleaves PIP2 into DAG and IP3. 
IP3 releases calcium from ER. cPKCs bind calcium, 
DAG and RACK undergoing a significant 
conformational change which leads to the full 
activation of the kinase. Adapted from Mochly-
Rosen et al., 2012. 
 
Being involved in cell proliferation, cell death and cell motility, it is not surprising that 
PKCs play crucial roles in invasion and metastasis. It is known that PKCε is upregulated 
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in several cancer types, whereas PKCα and PKCδ are downregulated (Griner and 
Kazanietz, 2007). A single mutation was identified in PKCα (D294G) in the invasive 
pituitary tumor as well as in the thyroid follicular adenomas and carcinomas (Alvaro et 
al., 1993; Prévostel et al., 1997). This mutation affects the hinge region between the 
regulatory and the kinase domains which impairs the translocation of PKCα. Furthermore, 
overexpression of PKCα in MCF7 breast cancer cells increases the anchorage-
independent growth, tumorigenesis and metastasis in mouse (Ways et al., 1995), while 
downregulation or inhibition of PKCα reduces cell migration in MDA-MB-231 breast 
carcinoma cells (Lønne et al., 2010). Similarly, overexpression of PKCβII in rat intestinal 
epithelial cells increases invasiveness via Ras/MEK pathway (Zhang et al., 2004). PKCε 
seems to play a role in invasive motility through the activation of RhoA and RhoC in 
head and neck squamous carcinoma (Pan et al., 2006), while depletion of PKCε in MDA-
MB-231 cells significantly decreases tumor growth and metastasis (Pan et al., 2005). It 
has also been realized that PKC might influence cancer cell motility through regulating 
integrins or MMPs (Liu et al., 2002; Ng et al., 1999; Parsons et al., 2002; Urtreger et al., 
2005). Although evidences exist to show that the link between PKC and invasive motility 
is strong, the underlying mechanisms of specific isozymes remain largely unknown. 
Moreover, some PKC isozymes, such as PKCα and PKCε, promote invasion and 
metastasis while some (like PKCδ) have a contradictory role. Therefore, phorbol ester 
induced tumor promotion needs to be revisited and further characterized.  
1.6	  Integrin	  and	  its	  role	  in	  cell	  invasion	  
Integrins are the major extracellular cell matrix receptors in metazoa without any 
homologues in prokaryotes, fungi, or plants (Hynes, 2002). Integrins are transmembrane 
heterodimers composed of α and β subunits, which couple extracellular matrix to actin 
cytoskeleton inside the cells enabling mechanosensing. Activated integrin dimers mediate 
downstream signaling through Rho GTPases, Src, PKB/Akt, MAPK and so on, playing 
key roles in development, immune responses, intracellular trafficking, cell proliferation 
and migration (Caswell and Norman, 2008). In mammals, there are 18 α subunits and 8 β 
subunits forming 24 different integrins (Figure 11) which appear to have distinct, 
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nonredundant functions. The 24 integrins have ligand binding specificities (Figure 11) 
and they show specific phenotypes in specific integrin knockout mice (Hynes, 2002).  
 
Figure 11. Mammalian integrins and 
their ligands. RGD (Arg-Gly-Asp) peptide 
containing ligands include fibronectin, 
vitronectin, thrombospondin, osteopontin,  
etc. Leukocyte integrin ligands include E-
cadherin, figrinogen, factor X, von 
Willebrand Factor, intracellular adhesion 
molecule, vascular cell adhesion molecule, 
and so on. Taken from Margadant et al., 
2011. 
 
1.6.1	  Integrin	  activation	  and	  endocytic	  trafficking	  
The heterodimeric transmembrane protein complex has a remarkable ability to transmit 
signals “bidirectionally”, from outside into the inside of the cell (“outside-in”) or on the 
contrary (“inside-out”). Integrins adopt low affinity, intermediate affinity or high affinity 
conformations on the plasma membrane (Figure 12). Activated integrins (high affinity) 
are recognized by the separation of the cytoplasmic tails of the α and β subunits and an 
extended open conformation of the extracelluar heads which can bind the ligands. 
Extracellular stimuli activate G-protein coupled receptors or receptor tyrosine kinases 
which in turn transduce signals leading to an allosteric conformational change of the 
heterodimer. Adaptor proteins talin and kindlin binding to the cytoplasmic tail of β 
subunit fully activates the integrins (inside-out). Active integrins subsequently bind their 
extracellular ligands, reinforce the α and β interaction and initiate “outside-in” signaling 
by recruiting adaptor proteins forming the links with actin filaments and other protein 
structures (Hynes, 2002; Margadant et al., 2011; Moser et al., 2009; Wickström and 
Fässler, 2011).  
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Figure 12. Activation of integrins. Extracellular stimuli transmit signals through receptors to 
change the integrin conformation from inactive to active through binding of talin and kindlin 
(inside-out). Active integrins bind extracellular ligands, and initiate outside-in signaling by 
further recruiting adaptor proteins such as talin and kindlin to connect to actin cytoskeleton, 
integrin clustering and a plethora of signaling cascades. Taken from Margadant et al., 2011. 
It is well established that integrins undergo endocytic transport contributing to the 
regulation of integrin surface levels upon signaling events (Bretscher, 1992; Caswell and 
Norman, 2006). The dynamic vesicular trafficking internalizes and recycles integrins of 
the cell thus exerting a pivotal role in focal adhesion assembly, matrix turnover and the 
dynamic redistribution of integrins to new adhesion sites in a moving cell (Caswell et al., 
2009). Integrins can follow either clathrin-dependent or clathrin-independent endocytic 
pathway to be internalized. Some integrins utilize more than one route. 
The cytoplasmic tail of β subunit contains a conserved NXXY motif (in which X 
represents any amino acid), which is found to recruit proteins to clathrin coated pits 
usually via interaction with endocytic adaptor proteins. Some clathrin adaptor proteins 
which contain phosphotyrosine binding domains, such as Numb, can interact with the 
NXXY motif. Numb localizes to the clathrin coated pits at the leading edge and interacts 
with β1 or β3 tails. Numb acting downstream of aPKC and PAR3 (proteinase-activated 
receptor 3) signaling regulates α5β1 and αvβ3 integrin internalization and directional cell 
migration (Nishimura and Kaibuchi, 2007). Another study has shown that albeit α5β1 
integrin internalization normally depends on the NXXY motif and clathrin, it can also be 
clathrin-independent by overexpressing the small GTPase Rab21 (Pellinen et al., 2008). It 
is possible that Rab21 induces α5β1 integrin endocytosis through caveolin-dependent 
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route. It has also been reported that α2β1 integrin internalizing through caveola is 
dependent on PKCα (Upla et al., 2004). Moreover, a direct association is found between 
β1 integrin cytoplasmic tail and PKCα (Ng et al., 1999).  
The internalized integrins may be returned to the plasma membrane or transported to the 
lysosomes for degradation. A portion of fibronectin bound α5β1 integrin is ubiquitinated 
on the α5 tail and transported to the lysosomes, which is required for proper fibroblast 
migration (Lobert et al., 2010). Most of the integrins are recycled either via Rab4-
dependent short route or Rab11/ADF-ribosylation factor 6 (Arf6)-dependent long 
recycling route. Recycling of integrins through either path depends on protein kinases 
such as PKB/Akt, PKC and PKD (Di Blasio et al., 2010; Ivaska et al., 2002, 2005; Li et 
al., 2005). Different routes of recycling affect integrin signaling on Rho GTPases and 
thus directional migration (Pankov et al., 2005; Vial et al., 2003; White et al., 2007).  
1.6.2	  Integrin	  in	  tumor	  cell	  migration	  and	  invasion	  
Most integrins activate focal adhesions and are required for proliferation and migration of 
cells in response to extracellular stimuli such as growth factors and cytokines. In spite of 
the fact that cancer cells have undergone transformation so that they require much less 
extracellular matrix cues and adhesions for their growth and proliferation, they still 
utilize integrin signals, especially in tumor initiation and progression (Guo and Giancotti, 
2004). Enhanced integrin signaling can promote EMT and extracellular matrix 
degradation, which in turn drives the migration of the cancer cell.  
Evidences implicate that loss of E-cadherin which plays a key role in cell-cell adhesion is 
required for EMT (Friedl and Alexander, 2011; Perl et al., 1998; Vleminckx et al., 1991; 
Yang et al., 2004). Overexpression of β1 integrin in normal epithelial cells disrupts 
adherens junctions (Gimond et al., 1999). In v-Src transformed cells, integrin signaling is 
enhanced to promote E-cadherin internalization and surpress E-cadherin expression 
(Avizienyte et al., 2002; Tan et al., 2001). Furthermore, integrins αvβ6 and αvβ8 might 
promote EMT through activating TGFβ (Mu et al., 2002; Munger et al., 1999; Wipff et 
al., 2007). It is also reported that αvβ3 integrin is upregulated in glioblastoma and 
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melanoma (Albelda et al., 1990; Gladson and Cheresh, 1991), where it possibly recruits 
and activates MMP2 to degrade extracellular matrix in the tumor microenvironment 
facilitating tumor invasion and metastasis (Brooks et al., 1996, 1998).  
By activating focal adhesion kinase (FAK) and thereby Src, integrins initiate a signaling 
cascade which can promote cell migration and invasion (Geiger et al., 2009; Hynes, 
2002). This signaling activates c-Jun N-terminal kinase (JNK) which may phosphorylate 
paxillin, a component of the focal adhesions. The phosphorylation of paxillin might 
regulate migration by promoting focal adhesion turnover (Huang et al., 2003; Miranti and 
Brugge, 2002). Downstream signaling also activates Rac and Rho which are key players 
in cell protrusion and contraction through regulating the actin cytoskeleton (Caswell et al., 
2009; Ridley et al., 2003). Furthermore, through integrins β1, β2, αvβ3 and α4β7, tumor 
cells develop cell-cell interactions with endothelial cells and platelets to mediate 
intravascular migration and adhesion arrest, thus facilitating extravasation. (Friedl and 
Alexander, 2011; Stoletov et al., 2010).  
During all the migration and invasion steps, integrin trafficking plays a pivotal role since 
it regulates the quantity and activity of integrin heterodimers on the plasma membrane as 
well as different membrane compartments so that integrins are able to exert their 
functions through signaling cascades. It was shown that mutant p53 significantly 
enhanced random cell motility and cell invasiveness into 3D matrix through promoting 
α5β1 recycling (Muller et al., 2009). Moreover, Rab11 trafficking of α6β4 integrin 
regulates hypoxia stimulated carcinoma invasion (Yoon et al., 2005). Rab25, a member 
of the Rab11 family, is reported to be strongly related to the aggressiveness of epithelial 
cancer (Cheng et al., 2004; Wang et al., 2004). Rab25 specifically regulates α5β1 integrin 
recycling by interacting directly with the β1 integrin cytoplasmic tail. Rab25 driving 
ovarian cancer cell invasion into 3D matrix depends on the interaction with β1 tail and 
the fibronectin ligand binding of α5β1 integrin. Rab25 promotes the delivery of α5β1 
integrin to the pseudopodial tips of the invading cell and keeps a pool of α5β1 integrin at 
the cell front. Therefore, directing integrin recycling and the vesicle localization 
facilitates the tumor cell invasion into 3D matrix (Caswell et al., 2007).  
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Because of the multi-faceted roles in tumor cell migration and invasion, integrins have 
become targets for cancer therapy, especially αvβ3 and α5β1 integrins (Cox et al., 2010). 
However, blocking one type of integrin might affect the trafficking of other integrins or 
growth factor receptors that are necessary for other functions (Caswell et al., 2009), 
which should be considered during the research and development of anti-integrin drugs. 
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2	  Aims	  of	  the	  project	  
FMNL2 was identified to have a role important for driving rounded mode of invasion 
downstream of RhoC (Kitzing et al., 2010). Genetic analysis discovered mutations of 
FMNL2 in cancer patients (Jones et al., 2008; Parsons et al., 2008). It was also reported 
that FMNL2 was upregulated in colorectal cancer and related to metastasis (Zhu et al., 
2008). RhoC, one of the regulatory factors of FMNL2 activity, was described in 
promoting invasion and metastasis in various cancer types (Clark et al., 2000; Hakem et 
al., 2005; Iiizumi et al., 2008; Pillé et al., 2005). It is worth further investigating the 
underlying mechanism of FMNL2 regulation and its role in cancer cell migration. 
Although the autoinhibition could be regulated by RhoC, there are evidences that indicate 
additional factors in the regulation of FMNL2 (Kitzing et al., 2010). Besides, the actin 
polymerization activity of FMNL2 remains elusive. Little is known about its subcellular 
localization. Hence it would be intriguing to broaden the views on the properties and 
functions of FMNL2. The major aim of my thesis was to investigate the molecular 
mechanism of the regulation of FMNL2 and its biological functions. Biochemical studies 
are to be performed in order to understand FMNL2 activity on actin assembly, and to 
identify new regulatory factors in FMNL2 autoinhibition. Investigation on the subcellular 
localization of FMNL2 in cells is important to understand the relationship of FMNL2 
with intracellular structures and the possible cellular functions. Functional analysis of 
FMNL2 and its new regulatory factors that direct FMNL2 localization and activity is 
aimed to uncover novel signaling regulation and to better understand the role of FMNL2 
in cancer cell invasion. This will provide insights for the formin research field and might 
be useful for the development of formins as anti-invasive cancer drug targets.  
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3	  Materials	  and	  Methods	  
3.1	  Materials	  
Table 2. Reagents used in this work. 
Reagent Manufacturer 
A23187 Sigma-Aldrich, Taufkirchen 
Acetic acid Roth, Karlsruhe 
Ampicillin AppliChem, Darmstadt 
Acrylamide (30%) – bisacrylamide (0.8%) 
mixture 
Roth, Karlsruhe 
Agar Roth, Karlsruhe 
ATP Sigma-Aldrich, Taufkirchen 
BES Sigma-Aldrich, Taufkirchen 
Bisindolylmaleimide I Calbiochem/Merck, Darmstadt 
Bovine serum albumin Roth, Karlsruhe 
Bromophenol blue Roth, Karlsruhe 
Coomassie Brilliant Blue G250 Roth, Karlsruhe 
DAPI Sigma-Aldrich, Taufkirchen 
DNA 1 kb plus marker Fermentas/Thermo Scientific, St. 
Leon-Rot 
DPBS (Ca2+ and Mg2+ free) PAA/GE Healthcare, Cölbe 
DMEM PAA/GE Healthcare, Cölbe 
Doxycycline hyclate Sigma-Aldrich, Taufkirchen 
Dry milk, fat free Roth, Karlsruhe 
DTT (1,4-dithiothreitol) Roth, Karlsruhe 
EDTA (ethylendiamine tetraacetic acid) Roth, Karlsruhe 
EGTA, molecular biology grade 
(ethylene glycol-bis-(β-aminoethyl ether)-
Sigma-Aldrich, Taufkirchen 
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Reagent Manufacturer 
N,N,N´,N´-tetraacetic acid) 
Ethanol, absolute Roth, Karlsruhe 
Ethidium bromide Sigma-Aldrich, Taufkirchen 
Enzymes for cloning Fermentas/Thermo Scientific, St. 
Leon-Rot 
FBS (fetal bovine serum) Invitrogen, Karlsruhe 
Flag (M2) -conjugated agarose Sigma-Aldrich, Taufkirchen 
Formaldehyde Roth, Karlsruhe 
Fugene HD Promega, Mannheim 
G418 sulfate PAA/GE Healthcare, Cölbe 
Glutaraldehyde Sigma-Aldrich, Taufkirchen 
Glycerol anhydrous Roth, Karlsruhe 
β-glycerolphosphate Calbiochem/Merck, Darmstadt 
Glycine Roth, Karlsruhe 
Glutathione, reduced Sigma-Aldrich, Taufkirchen 
Glutathione Sepharose 4B GE Healthcare, München 
Gö6976 Sigma-Aldrich, Taufkirchen 
H2O2 Sigma-Aldrich, Taufkirchen 
HEPES (N-(2-Hydroxyethyl)piperazine-N´-2-
ethane-sulfonic acid) 
Roth, Karlsruhe 
HiperFect Qiagen, Hilden 
Hydrochloric acid Roth, Karlsruhe 
Imidazole Merck, Darmstadt 
IPTG (Isopropyl β-D-1-thiogalactopyranoside) AppliChem, Darmstadt 
Kanamycin Roth, Karlsruhe 
Luminol Sigma-Aldrich, Taufkirchen 
Magnesium chloride hexahydrate Roth, Karlsruhe 
2-mercaptoethanol Merck, Darmstadt 
Methanol Roth, Karlsruhe 
myc-conjugated agarose Sigma-Aldrich, Taufkirchen 
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Reagent Manufacturer 
Ni-NTA agarose Qiagen, Hilden 
NP-40 Merck, Darmstadt 
dNTP set 
(2’-deoxynucleosides 5’-triphosphates) 
Fermentas/Thermo Scientific, St. 
Leon-Rot 
Optiprep Invitrogen, Karlsruhe 
32P-γ-ATP Hartmann Analytic, 
Braunschweig 
p-Coumaric acid Sigma-Aldrich, Taufkirchen 
Penicillin/Streptomycin PAA/GE Healthcare, Cölbe 
Phalloidin, Rhodamine- /AlexaFluor 488-
conjugated 
Invitrogen (Molecular Probes), 
Karlsruhe 
Phusion Hot Start II DNA Polymerase Fermentas/Thermo Scientific, St. 
Leon-Rot 
Polybrene Sigma-Aldrich, Taufkirchen 
Poly-L-Lysine Sigma-Aldrich, Taufkirchen 
Protease inhibitor cocktail tablets, complete, 
EDTA-free 
Roche, Mannheim 
Protein A/G beads Santa Cruz, Heidelberg 
Protein molecular weight standard, pre-stained Fermentas/Thermo Scientific, St. 
Leon-Rot 
SDS (sodium dodecylsulfate) Roth, Karlsruhe 
Sodium azide Merck, Darmstadt 
Sodium chloride Roth, Karlsruhe 
Sodium hydroxide Roth, Karlsruhe 
Sodium orthovanadate AppliChem, Darmstadt 
Sodium pyrophosphate Roth, Karlsruhe 
Sodium pyruvate PAA/GE Healthcare, Cölbe 
Streptavidin Sepharose High Performance GE Healthcare, Munich 
Sucrose Roth, Karlsruhe 
T4 DNA Ligase Fermentas/Thermo Scientific, St. 
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Reagent Manufacturer 
Leon-Rot 
TEMED  
(N,N,N',N'-tetramethyl-ethane-1,2-diamine) 
Roth, Karlsruhe 
TPA (12-O-tetradecanoylphorbol-13-acetate) 
Transferrin, AlexaFluor 488-conjugated 
Calbiochem/Merck, Darmstadt 
Invitrogen (Molecular Probes), 
Karlsruhe 
Tris (tris-(hydroxymethyl)-aminomethane) Roth, Karlsruhe 
Triton X-100 Merck, Darmstadt 
Trypsin-EDTA 0.05% PAA/GE Healthcare, Cölbe 
Tryptone Roth, Karlsruhe 
Tween-20 AppliChem, Darmstadt 
Yeast extract Roth, Karlsruhe 
PCR primers were ordered from Sigma-Aldrich, Taufkirchen. 
Ultra pure water was produced by water purification and deionization system OPTIPURE 
Analytic (membraPure GmbH, Bodenheim, Germany). 
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Table 3. Antibodies used in this work. 
Antibody Manufacturer 
anti-CD29 Beckman Coulter, Krefeld 
anti-CD49e AbD Serotec, Düsseldorf  
anti-CD49e BD Transduction Laboratories, 
Pharmingen, Heidelberg 
anti-Integrin α5β1 Merck/Millipore, Darmstadt 
anti-EEA1 BD Transduction Laboratories, 
Pharmingen, Heidelberg 
anti-Flag, horseradish peroxidase-conjugated Sigma-Aldrich, Taufkirchen 
anti-FMNL2 Atlas antibodies, Stockholm 
anti-GM130 BD Transduction Laboratories, 
Pharmingen, Heidelberg 
anti-GFP Santa Cruz, Heidelberg 
anti-HA, horseradish peroxidase-conjugated Sigma-Aldrich, Taufkirchen 
anti-MLC Sigma-Aldrich, Taufkirchen 
anti-myc, horseradish peroxidase-conjugated Sigma-Aldrich, Taufkirchen 
anti-phospho MLC Cell Signaling, Danvers 
anti-phospho-(Ser) PKC substrate Cell Signaling, Danvers 
anti-PKCα Cell Signaling, Danvers 
anti-PKCβ Santa Cruz, Heidelberg 
anti-PKCδ Cell Signaling, Danvers 
anti-PKCε Cell Signaling, Danvers 
anti-PKCζ Cell Signaling, Danvers 
anti-RhoC Cell Signaling, Danvers 
anti-TfR Invitrogen, Karlsruhe 
Goat anti-rabbit IgG 
horseradish peroxidase-conjugated 
Bio-Rad, Munich 
Sheep anti-mouse IgG 
horseradish peroxidase-conjugated 
GE Healthcare, Munich 
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Table 4. Biochemical kits used in this work. 
Kit Manufacturer 
Dual-Luciferase® Reporter Assay System Promega, Mannheim 
Nucleo Spin Extract II Kit Macherey-Nagel, Düren 
Nucleo Spin Plasmid Kit Macherey-Nagel, Düren 
PureLink™ HiPure Plasmid Maxiprep Kit Invitrogen, Karlsruhe 
 
Table 5. Composition of solutions used in this work. 
Solution Composition Remarks 
2× BBS transfection  BES               0.05 M pH 6.92 
buffer NaCl 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	   	   0.28 M autoclaved 
 Na2HPO4      0.0015 M  
 dissolved in deionized water  
ECL solution A Tris-HCl   100 mM 
Luminol   2.5 mM 
p-Coumaric acid  0.4 mM 
pH 8.5 
ECL solution B Tris-HCl   100 mM 
H2O2               0.018% v/v 
pH 8.5 
4×Laemmli buffer Glycerol   28% 
EDTA    10 mM 
SDS    5.7% 
2-mercaptoethanol  4.7 mg/ml 
Bromophenol blue  3.5 mg/ml 
Tris-HCl   286 mM 
pH 6.8 
LB agar NaCl    1% 
Yeast extract   0.5% 
Tryptone   1% 
Agar    1.5% 
autoclaved 
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Solution Composition Remarks 
 dissolved in deionized water  
LB medium NaCl    1% 
Yeast extract   0.5% 
Tryptone   1% 
dissolved in deionized water 
autoclaved 
PBS Na2HPO4   8 mM 
KH2PO4   1.5 mM 
NaCl    137 mM 
KCl    2.7 mM 
dissolved in deionised water 
pH 7.4 
PCR sample loading 
buffer (6×) 
Glycerol   30% 
Bromophenol blue  0.25% 
dissolved in deionised water 
 
SDS-PAGE 
separating gel 
Acrylamide   9.9% 
Bisacrylamide   0.26% 
TEMED   9.5 µM 
SDS    0.1% 
Tris-HCl   0.36 M 
(NH4)2S2O8   0.1% 
pH 8.8 
SDS-PAGE 
running buffer 
Glycine   192 mM 
SDS    0.1% 
Tris-HCl   25 mM 
pH 8.3 
SDS-PAGE 
stacking gel 
Acrylamide   5.9% 
Bisacrylamide   0.16% 
TEMED   14.5 µM 
SDS    0.1% 
Tris-HCl   0.12 M 
(NH4)2S2O8   0.15% 
pH 6.8 
TAE buffer EDTA    2 mM 
Tris    40 mM 
pH 8.0 
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Solution Composition Remarks 
Acetic acid   20 mM 
 dissolved in deionized water  
TBS-DM buffer Dry milk   5% 
NaCl    500 mM 
Tris-HCl   20 mM 
Tween-20   1% 
dissolved in deionized water 
pH 7.5 
TBST buffer NaCl    500 mM 
Tris-HCl   20 mM 
Tween-20   1% 
dissolved in deionized water 
pH 7.5 
Western blot 
blocking solution 
NaCl    500 mM 
Tris-HCl   20 mM 
Bovine serum albumin 5% 
NaN3    0.1% 
Tween-20   1% 
pH 7.5 
Western blot 
transfer buffer 
Glycine   192 mM 
Tris-HCl   25 mM 
Methanol   20% v/v 
pH 8.5 
 dissolved in deionized water  
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3.2	  Constructs	  and	  cloning	  
Expression constructs were generated and sequence-verified following standard cloning 
procedures. Flag-FMNL2, Flag-/myc-FMNL2-FH1-CT, Flag-mDia1, Flag-mDia1-CT 
and HA-RhoCV14 were described previously (Kitzing et al., 2010; Vaillant et al., 2008). 
myc-FMNL2, FMNL2-myc, FMNL2-GFP-myc, Flag-/myc-FMNL2-FH1-1023, Flag-
/myc-FMNL2-FH1-1045, and myc-FMNL2-FH3 (aa 262-484) were sub-cloned into 
EFpLink with N-terminal or C-terminal myc-tag as indicated. GST-FMNL2-959-CT for 
protein purification was cloned into pGEX-6P-1 (GE Healthcare). His-FMNL2-NT (23-
484) and His-FMNL2-F1F2-CT were cloned into pET20b (Novagen). His-mDia1-FH2 
(mDia1-CT) was described (Brandt et al., 2007). FMNL2-mCherry and FMNL2-GFP 
were cloned into pmCherryN1 or pEGFPN1 vectors (Clonetech). Point mutants FMNL2-
S1072A, S1072E, and ILI3A were generated by site-directed point mutation. Plasmids 
for generating inducible stable cell lines were kind gifts from Guang Hu. FMNL2 point 
mutants fused with EGFP or EGFP alone were amplified and inserted into pENTR11 
(Invitrogen) and shifted into pINDUCER20 (Meerbrey et al., 2011) by site-specific 
recombination with LR ClonaseTM II (Invitrogen).  Plasmids for FMNL2 overexpressing 
stable cell line were constructed by shifting FMNL-GFP, FMNL2-S1072A-GFP and 
FMNL2-S1072E-GFP from pEGFPN1 to pWPXL. Lentiviral pGIPZ-shFMNL2 was 
from Thermo Scientific. α5-integrin-GFP, GFP-PKCα and GFP-PKCα-T497A were 
described (Mostafavi-Pour et al., 2003; Tuomi et al., 2009). GFP-PKCα-CA was 
generated by deleting the first 30 amino acids and subcloned into pEGFPC1 vector 
(Clonetech). TGN38-YFP and mRFP-Lamp1 were gifts from Oliver Fackler (Uni 
Heidelberg). Human Rab4, Rab5 and Rab7 were kind gifts from Douglas Richardson 
(Harvard University). Primers used in this work are listed in Table 6. 
3.2.1	  Agarose	  gel	  electrophoresis	  
DNA samples were mixed with 6× PCR sample loading buffer and loaded to 1% agarose 
gels containing 10 µg/mL ethidium bromide. DNA fragments were separated on the gel 
in TAE buffer electrophoretically under constant voltage in a agarose gel chamber (Bio-
3. Materials	  and	  methods	  
	  	   38	  
Rad). The gel was later illuminated under UV light and visualized using INFINITY gel 
documentation system (PEQLab).  
Table 6. List of primers. 
Name Sequence (5’ -> 3’) 
FMNL2-1ClaFw GCGCGCATCGATGGCAACGCAGGGAGCATG 
FMNL2-
3279SpeRv 
GCGCGCACTAGTTCACATTGTTATTTCGGCACC 
FMNL2-
1023SpeRv 
GCGCGCACTAGTTCACTTTGATTTATGAGAAGG 
FMNL2-
1045SpeRv 
GCGCGCACTAGTTCAATATACATGTCTGTTATC 
FMNL2-1XhoFw  TACGATCTCGAGATGGGCAACGCAGGGAGCATGGATTC 
FMNL2-
1094KpnRv  
GCGCGCGGTACCCCCATTGTTATTTCGGCACC 
FMNL2-FH3ClaFw GCGCGCATCGATACAAAAGCCCTTGTCTTA 
FMNL2-FH3SpeRv GCGCGCACTAGTTCACTGAATTTTAATGGTCCC 
FMNL2-3216AFw AGGAGAGCCGTCAGGCGG 
FMNL2-3216ARv CCTGACGGCTCTCCTCAC 
FMNL2-3216EFw AGGAGAGAGGTCAGGCGG 
FMNL2-3216ERv CCTGACCTCTCTCCTCAC 
FMNL2-SalFw TACGATGTCGACATGGGCAACGCAGGGAGCAT 
FMNL2-
3279NotRv 
AGCTAAGCGGCCGCTCACATTGTTATTTCGGCACC 
FMNL2-PmeI1Fw TACGATGTTTAAACTAATGGGCAACGCAGGGAGCATGGA 
FMNL2-SpeGFPRv GCGCGCACTAGTTTACTTGTACAGCTCGTCCATGC 
FMNL2-2110Fw CTTGCCGCCACTTTAAGG 
FMNL2-2110Rv TAAAGTGGCGGCAAGATT 
FMNL2-LIAAFw CAAGAGGCCGCAGCAGAATTA 
FMNL2-LIAARv  TTCTGCTGCGGCCTCTTGCTG 
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Name Sequence (5’ -> 3’) 
PKCα-30XhoFw ACTATCCTCGAGCTAACGTGCACGAGGTGAAG 
PKCα-672KpnRv GCGCGCGGTACCTCATACTGCACTCTGTAAGAT 
 
3.3	  Cell	  culture,	  drug	  treatments,	  transfections	  and	  stable	  cell	  lines	  
HEK293, HEK293T, HeLa and A375M2 (kind gift from Erik Sahai, Cancer Research, 
London) cells were maintained in DMEM supplemented with 10% fetal bovine serum at 
37°C in a 5% CO2 environment. Inducible stable A375M2 cells were cultured with the 
addition of 800 µg/mL G418. When needed, cells were treated with 5 nM to 200 nM 12-
O-tetradecanoylphorbol-13-acetate (Calbiochem), 2 µM bisindolylmaleimide I 
(Calbiochem), 1 µM Gö6976 (Sigma) or 8 µM A23187 (Sigma).  
3.3.1	  Transfection	  of	  DNA	  
DNA plasmids were transfected with calcium phosphate method for HEK293 and 
HEK293T cells. Briefly, plasmids were mixed with autoclaved deionized distilled water. 
The same volume of 2×BBS buffer was added followed by adding 1/20 volume of 2.5 M 
CaCl2 dropwise. The transfection mixtures were incubated at room temperature for 20 
min before adding to the cells drop by drop. Cells were changed into fresh complete 
media after 3 hours. For transfection of HeLa cells, Fugene HD (Promega) was used 
according to manufacturer’s instructions. For one 6-well, plasmids were mixed in 96 µL 
serum free medium. 4 µL of Fugene HD was added and mixed by vortex. After 5 min 
incubation at room temperature, transfection mixtures were added to the cells.  
3.3.2	  Transfection	  of	  siRNA	  
siRNAs were transfected using HiperFect (Qiagen) following manufacturer’s 
instructions. For one 6-well, 20 µM siRNA in the volume of 2 µL was mixed with 186 µL 
serum free media and 12 µL HiperFect. After 5min incubation at room temperature, the 
transfection mixtures were added to cells in a total volume of 2 mL. All siRNAs were 
purchased from Qiagen. Transfection of both siRNA and DNA in one experiment was 
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achieved by transfecting siRNA on the day of splitting cells and transfecting DNA 
subsequently on the following day. siRNA targeting sequences are listed in Table 7.  
Table 7. List of siRNA targeting sequences. 
Name Targeting sequence (5’ -> 3’) 
human RhoC CACCATGGCTGCAATCCGAAA 
human FMNL2, targeting 3’-UTR, 3’-
AlexaFluor 555 modified 
CTGCGGGCACATTCCCATAAA 
human PKCα AACCATCCGCTCCACACTAAA 
human PKCβ CCGGATGAAACTGACCGATTT 
human PKCδ AACTCTACCGTGCCACGTTTT 
human PKCε CCCGACCATGGTAGTGTTCAA 
human PKCζ CGGAAGCATGACAGCATTAAA 
 
3.3.3	  Generating	  stable	  cell	  lines	  by	  virus	  transduction	  
A375M2 or HeLa stable cell lines were generated by lentiviral transduction. Viruses were 
produced by transfecting HEK293T cells with packaging plasmid psPAX2, envelope 
plasmid pMD2G and expressing plasmids pINDUCER20-/pWPXL-GFP, FMNL2-
S1072A-GFP, FMNL2-S1072E-GFP, FMNL2-ILI3A-GFP, FMNL2-ILIS4A-GFP or 
FMNL2-ILI3ASE-GFP. Supernatants were harvested 48 h after transfection and filtered 
through 0.45 µm filter. A375M2 or HeLa cells were infected by the virus supernatant 
with the addition of 10 µg/mL Polybrene. 48 h after infection, cells were trypsinized and 
passaged. To induce the expression of the desired protein when needed, doxycycline was 
applied to the cells at 1 µg/mL. 
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3.4	  Analysis	  of	  protein	  expression	  from	  cultured	  cells	  
3.4.1	  Isolation	  of	  protein	  from	  cells	  
Cell culture media were removed from cultured cell. Cells were lysed by adding 1× 
Laemmli buffer at the ratio of 10 µL per 1×105 cells. The lysates were scraped from the 
cell culture dish into Eppendorf tubes and incubated at 95°C for 10 to 15 min. Extracted 
cell lysates were subjected to SDS-PAGE immediately or stored at -20°C. 
3.4.2	  SDS-­‐PAGE	  
Proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) using Mini-PROTEAN Tetra Cell gel system (Bio-rad). From 8% to 13% 
separating gel and 6% stacking gel (Table 5) were used according to the different sizes of 
the proteins which were to be separated. Gels were casted and polymerized in a vertical 
glass space and assembled into the vertical Tetra Cell chamber following manufacturer’s 
instructions. The chamber was filled with SDS running buffer (Table 5). Cell lysates and 
standard pre-stained protein marker were loaded into the wells. Proteins were 
electrophoretically separated at constant voltage (80 V for stacking gel and 120 V for 
separating gel). The gels were subjected to coomassie blue staining or transfer. 
3.4.3	  Transfer,	  blocking	  and	  detection	  of	  the	  proteins	  by	  antibodies	  
SDS-PAGE gels and 0.22 or 0.45 µm nitrocellulose membranes (Whatman) were 
assembled into a Mini Trans-Blot module and then into the Mini Trans-Blot 
Electrophoretic Transfer Cell (Bio-rad) following manufacturer’s instructions. The 
transfer cell chamber was filled with Western blotting transfer buffer (Table 5) and 
proteins were transferred from the gel to the membrane at constant voltage of 100 V for 
45 min to 1.5 h.  
After transfer, membranes were placed into blocking buffer (Table 5) and incubated for 1 
h at room temperature. Different primary antibodies were diluted in the blocking buffer 
and incubated with the membranes on a shaker for 1 to 2 h at room temperature or 
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overnight at 4°C subsequently. Membranes were washed 10 min each for three times 
with TBST (Table 5) and incubated with secondary antibodies in blocking buffer for 1 h 
at room temperature when necessary. Membranes were washed again 10 min each for 
three times with TBST before developing. Enhanced chemiluminescence (ECL, Table 5) 
was used to detect the horseradish peroxidase-conjugated antibodies. Films (Fuji) were 
exposed on top of the membrane with ECL at different time points in a dark room and 
developed with the developing machine. The primary and secondary antibody dilutions 
are listed in Table 8.  
Table 8. List of antibody dilutions used in this work. 
Antibody Dilutions 
anti-CD29 1:1000 
anti-CD49e 1:1000 
anti-Flag, horseradish peroxidase-conjugated 1:5000 
anti-FMNL2 1:2000 
anti-GFP 1:3000 
anti-HA, horseradish peroxidase-conjugated 1:2000 
anti-MLC 1:500 
anti-myc, horseradish peroxidase-conjugated 1:2000 
anti-phospho MLC 1:1000 
anti-phospho-(Ser) PKC substrate 1:1000 
anti-PKCα 1:1000 
anti-PKCβ 1:200 
anti-PKCδ 1:1000 
anti-PKCε 1:1000 
anti-PKCζ 
anti-RhoC 
1:500 
1:1000 
anti-TfR 1:500 
Goat anti-rabbit IgG 
horseradish peroxidase-conjugated 
1:5000 
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Antibody Dilutions 
Sheep anti-mouse IgG 
horseradish peroxidase-conjugated 
1:3000 
 
3.5	  Protein	  purification	  
The expression plasmid was transformed into E. coli BL21 (DE3). Bacteria were cultured 
in LB medium at 37°C until OD=0.6 and induced with 200 µM IPTG at 22°C for 16 h. 
GST fusion protein was purified using Glutathione Sepharose 4B beads (GE Healthcare) 
as described before (Brandt et al., 2007). Briefly, bacteria were harvested by 
centrifugation and lysed by sonication in lysis buffer (50 mM Tris-HCl pH 8.0, 150 mM 
NaCl, complete protease inhibitors). After centrifugation at 13,000 rpm at 4°C for 45 
min, supernatant was collected and loaded to pre-equilibrated Glutathione Sepharose 4B 
beads. Beads were washed three times with high-salt washing buffer (50 mM Tris-HCl 
pH 8.0, 500 mM NaCl) and three times with non-salt washing buffer (50 mM Tris-HCl 
pH 8.0) subsequently before eluting with elution buffer (50 mM Tris-HCl pH 8.0, 10 mM 
Glutathione reduced).  
6×His fusion protein was purified using Ni-NTA agarose beads (Qiagen). Bacteria were 
lysed in 1×PBS pH 7.4, 30 mM Imidazole and 1% NP-40 with complete protease 
inhibitors. After centrifugation, supernatant was collected and loaded to pre-equilibrated 
Ni-NTA beads followed by three times high salt washing (1×PBS pH 7.4, 20 mM 
Imidazole, 350 mM NaCl) and three times low salt washing (1×PBS pH 7.4, 20 mM 
Imidazole). 6×His fusion proteins were eluted in fractions with elution buffer (1×PBS pH 
7.4, 350 mM Imidazole).  
Fractions were loaded to SDS-PAGE gels and subjected to coomassie blue staining to 
visualize the proteins of interests. Fractions with desired protein were pooled and 
dialyzed in 20 mM Hepes (pH 7.4), 25 mM MgCl2, 5 mM EDTA and 5 mM DTT. For 
3. Materials	  and	  methods	  
	  	   44	  
formin FH2 containing proteins, dialyzing buffer contained 2 mM Na3PO4, pH 7.4, 50 
mM NaCl, 0.1 mM MgCl2, 0.1 mM EGTA and 0.5 mM DTT (Chhabra and Higgs, 2006). 
3.6	  In	  vitro	  kinase	  assay	  
Purified recombinant GST fusion Protein kinase C protein isoforms were purchased from 
ProQinase GmbH. 20 ng of each PKC isoform and 1 µg substrate protein were incubated 
in 50 mM Hepes (pH 7.4), 150 mM NaCl, 5 mM EDTA, 5 mM DTT, 25 mM MgCl2, 
0.02% Triton X-100, 1 mM ATP and 5 µCi 32P-γ-ATP at 30°C for 15 min. Kinase 
reaction was stopped by adding the 1×Laemmli buffer (Table 5). After running SDS-
PAGE and fixation of the gel, films were exposed on top of the gel in the dark room or at 
-80°C and developed at different time points. 
3.7	  Biotin-­‐strepdavidin	  pull-­‐down	  assay	  
24 hours after transfection, HEK293 cells were scraped and lysed using lysis buffer 
containing 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 2 mM EDTA, 0.1% Triton X-100, 
1 mM DTT, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM sodium 
orthovanadate, and complete protease inhibitors (Roche). Cell lysates were centrifuged 
(13,000 rpm, 10 min at 4°C) and the supernatants were collected. 10 µL of biotinylated 
α5/β1 integrin cytoplasmic tail peptides (5 µg/µL each) were pre-incubated with cell 
lysates respectively for 4 h (Pellinen et al., 2008; Tuomi et al., 2009). The peptide 
sequences were: β1 integrin cytoplasmic tail: Biotin-
HDRREFAKFEKEKMNAKWDTGENPIYKSAVTTVVNPKYEGK; α5 integrin 
cytoplasmic tail: Biotin-YKLGFFKRSLPYGTAMEKAQLKPPATSDA. Strepdavidin 
sepharose beads (GE Healthcare) were washed with lysis buffer and added to the pre-
incubated mixture after the 4 h pre-incubation. Another 1 h incubation was conducted 
before washing the beads three times with lysis buffer. 1×Laemmli buffer (Table 5) was 
added and samples were subjected to SDS-PAGE gel and Western blotting. 
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3.8	  Immunoprecipitation	  
Cells were harvested 24 or 48 h after transfection by scraping and lysed in lysis buffer 
containing 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 2 mM EDTA, 0.1% Triton X-100, 
2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM sodium orthovanadate, 
and complete protease inhibitors (Roche). Supernatants were collected after 
centrifugation (13,000 rpm, 10 min at 4°C) and incubated with Flag/myc-conjugated 
agarose beads (Sigma) or Protein A/G beads (Santa Cruz) together with antibodies for 1 
to 5 h at 4°C. Beads were centrifuged and washed three times with lysis buffer. 
1×Laemmli buffer （Table 5）was added and samples were subjected to SDS-PAGE gel 
and Western blotting.  
3.9	  MAL/SRF	  luciferase	  reporter	  assay	  
MAL/SRF luciferase assays were performed as described previously (Brandt et al., 
2009). Briefly, HEK293 cells were transfected with plasmids of genes of interests, 
p3DA.luc and pRL-TK reporter plasmids. 24 h after transfection, cell media were 
removed and cells were washed once with PBS. 200 µL 1× Passive lysis buffer 
(Promega) was added per 6-well. Cells were lysed on ice for 20 min, scraped and 
centrifuged at 13,000 rpm for 15 min at 4°C. From 5 to 20 µL cell lysates were used for 
each assay. Firefly and Renilla luciferase signals were recorded sequentially by 
Luminoscan Ascent Microplate Luminometer (Thermo Scientific) using the Ascent 
software (Thermo Scientific) with 900 ms integration time. Firefly signal was normalized 
to Renilla signal for each sample. 
3.10	  Membrane	  flotation	  
HeLa cells were seeded 48 h or HEK293 cells were transfected 24 h before analysis. 
Membrane flotation assays were performed as described (Pan et al., 2012). 200nM TPA 
or DMSO were applied to the cells for 30 min at 37°C. Cells were washed once with ice 
cold PBS and lysed in TNE buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM 
EDTA, protease inhibitors and phosphatase inhibitors) for 20 min. The cell lysates were 
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passed through 25G syringe needle 20 times. After brief centrifugation, supernatants 
were mixed with 67% Optiprep (Invitrogen) and loaded to SW60 centrifuge tubes. Each 
sample was overlaid with 2.5 mL 28% Optiprep and 600 µL TNE buffer carefully 
without disturbance. Ultracentrifugation was performed with SW60 rotor at 35,000 rpm 
for 3 h at 4°C (Beckman Coulter). 500 µL fractions were collected with the 2nd and 8th as 
the membrane and soluble fractions respectively. 30 µL of each fraction was subjected to 
Western blotting analysis. 
3.11	  Subcellular	  fractionation	  with	  discontinuous	  sucrose	  density	  gradient	  	  
HeLa cells were seeded 48 h or HEK293 cells were transfected 24 h before analysis. 
Sucrose gradient analysis was performed as described (Pan et al., 2012). In short, 
discontinuous sucrose gradient was poured 16 h before use at 4°C, which was composed 
of 700 µL of each 0.5 M, 0.8 M, 1.0 M, 1.2 M and 1.5 M sucrose in TE buffer (50 mM 
Tris-HCl pH 7.4, 5 mM EDTA) from top to bottom in a centrifuge tube suitable for 
SW60 rotor. 200nM TPA or DMSO were applied to the cells for 30 min at 37°C when 
necessary. Cells were washed once with ice cold PBS and lysed in 1 mL TNE buffer (50 
mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM EDTA, protease inhibitors and phosphatase 
inhibitors) for 20 min. The cell lysates were passed through 25G syringe needle 20 times 
and subjected to centrifugation at 4,000 rpm for 6 min. 750 µL of the supernatant was 
loaded to the top of the sucrose gradient. Ultracentrifugation was performed with SW60 
rotor at 35,000 rpm for 1.5 h at 4°C (Beckman Coulter). 420 µL fractions were collected 
from the top of the tube and fractions were subjected to Western blotting analysis. 
3.12	  Immunocytochemistry	  
HeLa cells were seeded on cover slips in 6-well plates. 24 h or 48 h after transfection, 
cells were washed with PBS and fixed with 8% formaldehyde for 10 min at room 
temperature. After washing with PBS, 0.02% Triton-X 100 in PBS was used to 
permeablize cells for 10 min. Cells were blocked with 5% BSA in PBS for 1 h at room 
temperature. Primary and secondary antibodies were diluted in the blocking solution and 
incubated with the coverslips for 1 h each with three times PBS washing between the two 
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steps. DAPI staining was performed for 10 min when indicated. Coverslips were then 
mounted on the glass slides using fluorescent mounting media (Dako).   
3.13	  Live	  cell	  imaging	  
HeLa cells were seeded on cover slips in 6-well plates. 24 h or 48 h after transfection, 
cover slips seeded with cells were inserted into a customized imaging dish and mounted 
to the microscope objective. Live cell imaging was performed at 37°C, in a CO2 chamber. 
Images were acquired every 5 to 10 s with a LSM 700 confocal microscope (Zeiss) and 
the Zen software (Zeiss), using the 63×/1.4 oil objective. Drugs were applied to the cells 
directly at the microscope while scanning. EGFP and mCherry or AlexaFuor 555 
channels were scanned sequentially by line within 1.94 s. Images were later processed 
with Image J software. 
3.14	  Invasion	  assays	  and	  image	  analysis	  
Inverted transwell invasion assays were performed as described (Kitzing et al., 2010). 
Cells were seeded 24 h before the assay. Doxycycline (1 µg/mL) was applied to the 
inducible stable cell lines in all the solutions. Upper chambers of the Transwell inserts 
(Greiner Bio-one) were coated with 50 µL growth factor reduced Matrigel (BD 
Biosciences) and polymerized for 60 min at 37°C. The inserts were inverted allowing cell 
seeding (6,000 cells per inserts for A375M2 cells) and adhering on the outer bottom. 
After 3 h, the Transwell inserts were reverted. The upper chambers were filled with 
medium containing 20% fetal bovine serum and the lower chamber with medium 
containing 0.5% fetal bovine serum. Cells were invading for 48 h before fixation, 
permeabilization and subsequent staining with DAPI and rhodamine phalloidin. Confocal 
z-stacks of 100 µm were acquired every 5 µm for five random imaging fields of each 
insert with LSM 700 confocal microscope (Zeiss), using the 20×/0.75 objective and the 
ZEN software (Zeiss). Quantification of the invaded (more than 15 µm) and non-invaded 
cell number was achieved using the Image J Analyze Particle function counting the 
number of the nucleus.  
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3.15	  Analysis	  of	  fluorescence	  intensity	  changes	  on	  the	  plasma	  membrane	  
The analysis was performed by Haisen Ta (Max Planck Institute for Biophysical 
Chemistry, Göttingen). In brief, 2D fluorescence intensity images with time stamps were 
segmented by Sobel edge detection with building function in MATLAB to identify the 
plasma membrane region. The fluorescence intensity was summed up in membrane 
region for each cell, and normalized by their maximum intensity. Photo bleaching was 
corrected by the overall intensity of the whole cell. Statistics was given on the normalized 
fluorescence intensity at each time point. 
3.16	  Actin	  polymerization	  assay	  with	  fluorescence	  microscopy	  
Unlabeled actin monomers (2.4 µM, Hypermol) were added to 50 µL polymerization 
buffer (2 mM Tris-HCl, pH 8.0, 0.5 mM DTT, 0.2 mM ATP, 1.1 mM MgCl2, 50 mM 
KCl, 1 mM EGTA, 10 mM imidazole, pH 7.0 and 0.01% NaN3) containing formin FH2 
domain proteins. At different time points, take 1 µL of the reaction and dilute it in 80 µL 
0.4×KMEI buffer (20 mM KCl, 4 mM MgCl2, 4 mM EGTA, and 40 mM imidazole, pH 
7.0) (Chhabra and Higgs, 2006) with 0.5 µL Alexa 488-phalloidin (6.6 µM, Invitrogen). 
From each dilutions, take 20 µL mixing with fluorescent mounting medium (Dako) and 
drop onto poly-L-Lysine coated coverslips, then mount on glass slides before going to 
microscope. Images of actin filaments were taken with Nikon Eclipse Ti epifluorescence 
microscope using the 100×/1.4 objective and NIS-Element AR software (Nikon).  
3.17	  Pyrenyl-­‐actin	  assembly	  assay	  
Pyrenyl-actin assembly assays were adapted from previously described protocols 
(Kitzing et al., 2007). For the assays using cell lysates, HEK293 cells were transfected 
with formin proteins. 24 h after transfection, cells were lysed in lysis buffer containing 20 
mM Tris-HCl (pH 7.4), 150 mM NaCl, 2 mM EDTA, 0.1% Triton X-100, 2.5 mM 
sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM sodium orthovanadate, and 
complete protease inhibitors (Roche). After brief centrifugation at 13,000 rpm for 10 min, 
500 µL supernatant of each sample were collected and dialyzed against dialysis buffer (2 
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mM Na3PO4, pH 7.4, 50 mM NaCl, 0.1 mM MgCl2, 0.1 mM EGTA, 0.5 mM DTT) for 1 
h. All samples were diluted to a total protein concentration of 20 mg/mL. For the assays 
using eluted Flag tag proteins, immunoprecipitation was performed as described in the 
section 3.7. After final washing, Flag beads were eluted three times with 40 µL Flag 
peptide (Sigma) elution buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 
200 µg/mL Flag peptide). Fractions were pooled and dialyzed with dialysis buffer for 1 h. 
To start the pyrenyl-actin assemply assay, 5 to 10 µL protein was diluted in 80 µL 
dialysis buffer, followed by sequentially adding 10 µL of energy buffer (150 mM creatine 
phosphate, 20 mM ATP, 2 mM EGTA, 20 mM MgCl2) and 10 µL of pyrenyl-actin (final 
concentration 2 µM, 10% labeled, Hypermol). Fluorescence was immediately monitored 
for 5 to 10 min at 407 nm with an excitation at 365 nm using a SHIMADZU RF-5301PC 
spectrofluorophotometer. 
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4	  Results	  
FMNL2, along with FMNL1 and FMNL3, belong to the formin-like subfamily of 
mammalian formins (Figure 13A). FMNL3 was reported to be a formin lacking 
autoinhibition mediated by N- and C-termini interaction, while FMNL1, FMNL2 and 
FMNL3 all have the capacity to bundle actin filaments (Harris, 2006; Vaillant et al., 
2008). FMNL2 is widely expressed in human tissues, especially in central and peripheral 
nervous system (Gardberg et al., 2010). It has been reported that FMNL2 is required for 
amoeboid mode of invasion downstream of RhoC (Kitzing et al., 2010). Other properties 
of FMNL2 remain elusive.  
4.1	  The	  role	  of	  FMNL2	  in	  actin	  polymerization	  
4.1.1	  FMNL2	  is	  a	  poor	  actin	  nucleator	  
Formin proteins are the largest group of actin nucleators. Unlike FMNL1 and FMNL3, 
the actin nucleation activity of FMNL2 was poorly studied. In order to understand the 
actin assembly properties of FMNL2, plasmids expressing 6×His tagged FMNL2 N-
terminus (FMNL2-NT, aa 1-484), FH1 domain to C-terminus (FMNL2-FH1-CT, aa 504-
1092) and FH2 domain to C-terminus (FMNL2-FH2-CT, aa 599-1092) were constructed 
(Figure 13A) and proteins were purified (Kitzing et al., 2010; Moseley et al., 2006; 
Vaillant et al., 2008). Pyrenyl-actin polymerization assays showed that FMNL2 inhibited 
actin polymerization. The more FMNL2-FH1-CT added to the reaction, the rate became 
slower (Figure 13B), indicating that purified FMNL2-FH1-CT might strongly bind actin 
monomers or the barbed ends of the filaments sequestering nucleation and/or elongation. 
Additionally, FMNL2-NT exhibited no activity on actin assembly in pyrenyl-actin assay 
while FMNL2-FH2-CT seemed to inhibit actin assembly (Figure 13B).  
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Figure 13. Pyrenyl-actin polymerization assays implicate that FMNL2 is a poor actin 
nucleator. A. Schemes of FMNL2 proteins described in the experiments. GBD: GTPase binding 
domain; FH1/2/3: formin homology 1/2/3; WH2: WASP homology 2; DAD: diaphanous 
autoregulatory domain. Numbers indicate boundaries of amino acids. B. Pyrenyl-actin assays 
using purified proteins from bacteria. C. Pyrenyl-actin assays using HEK293 cells lysates 
expressing different proteins. D. Pyrenyl-actin assays using Flag tagged mDia1-CT purified from 
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HEK293 lysates. E. Pyrenyl-actin assays using Flag tagged proteins purified from HEK293 
lysates. 
However, purified protein from bacteria might exhibit different properties due to lack of 
the co-/post-translational modification system and regulating partners of eukaryotes. 
Thus, pyrenyl-actin assays were subsequently conducted using HEK293 cell lysates 
expressing mDia1 C-terminus containing the FH2 domain (mDia1-CT) or FMNL2-FH1-
CT. mDia1 is known to be a potent actin nucleator and the cell lysate expressing mDia1-
CT showed significant activity on actin assembly comparing to the control cell lysate or 
the actin alone. Cell lysate expressing FMNL2-FH1-CT exhibited almost the same basal 
activity as the control cell lysate, showing that expression of FMNL2-FH1-CT in cells 
could not additionally increase actin assembly more than control lysate (Figure 13C). 
Moreover, efforts were made to purify proteins from HEK293 cell lysates. Flag-tagged 
proteins were overexpressed in HEK293 cells and immunoprecipitated. Flag peptides 
were used to elute the proteins from the Flag antibody-conjugated agarose beads. The 
eluted proteins were also applied to pyrenyl-actin polymerization assay. mDia1-CT 
showed potent activity on actin assembly as shown in Figure 13D. There was no obvious 
activity from FMNL2 full length (FMNL2-FL), while FMNL2-FH1-CT, FMNL2-FH1-
1023 (without WH2 and DAD domains) and FMNL2-FH1-1045 (without DAD domain) 
inhibited actin assembly to the same extent (Figure 13E). Interestingly, when FMNL2-
FH1-CT, FMNL2-FH1-1023 or FMNL2-FH1-1045 was pre-incubated with mDia1-CT 
and applied to the pyrenyl assay, the polymerization activity of mDia1-CT was inhibited 
(Figure 13E). Hence, it is possible that the FH2 domain of FMNL2 strongly bind the 
barbed ends. In the closely related FMNL3, it was reported that both FH2 and WH2 
bound actin monomers and barbed ends (Heimsath and Higgs, 2012; Thompson et al., 
2013). In fact, in the Flag-IP elution, an actin band was detected together with FMNL2-
FH1-CT indicating that FMNL2 FH2 or WH2 domain strongly interact with actin (data 
not shown).  
Since FMNL2 did not show obvious actin assembly activity in pyrenyl-actin assays with 
proteins from three different sources, it was necessary to visualize the effects of FMNL2 
on actin assembly. After 30 or 60 s reaction of actin monomers and formin proteins in 
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polymerization buffer, samples were collected and AlexaFluor 488-phalloidin was used 
to stain and stabilize the polymerized actin seeds (Figure 14). In control reaction, 
nucleation happened at a quite slow rate, showing few differences between 30 s and 60 s 
reactions. mDia1-CT as a potent nucleator gave prominent actin filaments within 30 s and 
more within 60 s. FMNL2-FH1-CT and FMNL2-FH2-CT showed no differences in 
comparison to control condition (Figure 14). Therefore, both pyrenyl-actin assembly 
assay and actin assembly assay with phalloidin staining indicate that FMNL2 is a poor 
actin nucleator in vitro. 
 
Figure 14. Visualizing actin filaments assembled under various conditions by microscopy. 
Actin assembly reactions were conducted in polymerization buffer. Reactions were stabilized and 
stained with AlexaFluor 488-phalloidin at different time points and visualized by epi-
fluorescence microscope. Amounts of the proteins used were: 0.5 µM FMNL2-FH1-CT, 0.5 µM 
FMNL2-FH2-CT and 75 nM mDia1-CT. Scale bar: 5 µm.  
To further understand the cellular context of FMNL2 and actin filaments, FMNL2-FH1-
CT, FMNL2-FH1-1023 or FMNL2-FH1-1045 was expressed in HeLa cells. The 
expression of all three proteins induced robust formation of stress fibers (Figure 15). 
Interestingly, FMNL2-FH1-CT and FMNL2-FH1-1045 exhibited a prominent 
accumulation in the nucleus of the cells which resembles the case of mDia1-FH1-CT. 
mDia1-FH1-CT localization in the nucleus is dependent on a C-terminal cryptic nuclear 
localization sequence (NLS) after the FH2 domain (Copeland et al., 2007). FMNL2-FH1-
1023 lost the nuclear localization and distributed in the cytoplasm, implicating that the 
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possible NLS in FMNL2 lies between amino acid 1023 and 1045. Given the fact that 
there are several lysine and arginine residues within this region, the NLS might reside 
within the WH2 domain (Figure 28A). The reason why FMNL2 harbors such a signal and 
how it is regulated needs further investigation. As shown in Figures 13 and 14, how 
FMNL2 as a poor nucleator in vitro regulates stress fiber formation also needs further 
study. 
 
Figure 15. FMNL2 derivatives induce stress fibers and accumulate in nucleus. myc-FMNL2-
FH1-CT, myc-FMNL2-FH1-1045 and myc-FMNL2-FH1-1023 (red) were expressed in HeLa 
cells. Nucleus was visualized with DAPI (blue) and F-actin was visualized with phalloidin 
(green). All three induced stress fiber while only myc-FMNL2-FH1-CT and myc-FMNL2-FH1-
1045 accumulated in nucleus. Scale bar: 10 µm. 
4.1.2	  The	  actin	  polymerization	  activity	  and	   the	  plasma	  membrane	   localization	  
of	  FMNL2	  are	  regulated	  by	  RhoC	  
Previously, it was shown that the constitutively active Rho GTPase, RhoC V14, 
interacted with the GBD of FMNL2, while the closely related RhoA or RhoB did not 
(Kitzing et al., 2010). However, it was not shown where FMNL2 localized or how the 
actin assembly activity of FMNL2 was regulated in cells. In order to verify the cellular 
role that RhoC plays on FMNL2, FMNL2-mCherry was transiently expressed in HeLa 
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cells (Figure 16A). Under control condition, around 90% cells showed that FMNL2 
predominantly localized on the plasma membrane and also distributed in the cytoplasm 
but not homogeneously. When RhoC was silenced with siRNA or inhibited by C3 
transferase, only about 30% of cells showed proper plasma membrane localization of 
FMNL2. Western blot was shown to verify the knockdown efficiency of RhoC (Figure 
16A). To functionally explore the role of RhoC on FMNL2 actin assembly activity, 
MAL/SRF luciferase reporter assay was performed (Copeland and Treisman, 2002; 
Grosse et al., 2003). Expression of autoinhibited FMNL2 or mDia1 full length proteins 
showed no activity as control (Figure 16B). Autoinhibition was released when 
constitutively active RhoC V14 was co-expressed with FMNL2, while constitutively 
active RhoA V14 did not induce FMNL2 activity. This implicates that active RhoC 
regulates FMNL2 activity on actin dynamics. In contrast, mDia1 was activated to the 
same extend by both RhoC V14 and RhoA V14, suggesting that mDia1 is modulated by 
both Rho GTPases as previously reported (Rose et al., 2005; Watanabe et al., 1999). 
 
Figure 16. RhoC regulates the localization and activity of FMNL2. A. FMNL2-mCherry and 
siCtrl, siRhoC or C3 were co-expressed in HeLa cells. Knockdown of RhoC is shown. Cells 
expressing FMNL2-mCherry with plasma membrane localization were quantified over the total 
cell number counted. Scale bar, 10 µm. Error bar, + s.e.m. (n=3). B. HEK293 cells expressing full 
length FMNL2 or mDia1 together with RhoC V14 or RhoA V14 as indicated, MAL/SRF reporter 
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3DA.Luc and Renilla luciferase pRLTK. SRF activity was measured 24 h after transfection. Error 
bar: + s.e.m. (n=3), p<0.05. 
4.2	  FMNL2	  is	  phosphorylated	  by	  PKC	  and	  the	  phosphorylation	  is	  enhanced	  
by	  RhoC	  
4.2.1	  FMNL2	  is	  phosphorylated	  by	  PKC	  
Although autoinhibition of FMNL2 depends on the DID-DAD interaction (Vaillant et al., 
2008), a previous study showed that inhibition of C-terminal activity of FMNL2 required 
higher concentration of N-terminus (Kitzing et al., 2010). It was reported that the formin 
FHOD1 could be activated through phosphorylation by ROCK (Hannemann et al., 2008; 
Takeya et al., 2008). The DAD domain of FHOD1 is composed of the core motif and its 
C-terminal flanking region is abundant in basic residues (Takeya et al., 2008). Similarly 
the flanking sequence of FMNL2 DAD core region is also abundant in basic residues. 
There is a conserved Ser residue (S1072) which resides in the basic region indicating that 
it might be a target of kinases (Figure 17A). However, the R/KR/KXS/THydR/K (X 
stands for any residue, Hyd stands for hydrophobic residue, R: Arg, K: Lys, S: Ser, T: 
Thr) motif is the substrate sequence motif of classical PKC (Nishikawa et al., 1997). In 
the flanking polybasic region of FMNL2 DAD core, the RRSVR motif resembles the 
sequence motif of cPKC substrate (Figure 17A). Therefore, FMNL2 or mDia1 was 
overexpressed in cells and treated with either DMSO, the PKC activator 12-O-
tetradecanoylphorbol-13-acetate (TPA) or the PKC inhibitor bisindolylmaleimide I (BIM 
I). MAL/SRF reporter assay showed that both FMNL2 and mDia1 under control 
conditions were autoinhibited formins that showed low activity on actin assembly. In 
contrast, under TPA treatment, FMNL2 exhibited a robust activity while mDia1 did not. 
When PKC activity was inhibited by BIM I, both FMNL2 and mDia1 kept inactive in 
spite of the presence of TPA (Figure 17B). Albeit phoborl esters were known to be 
unspecific, the reporter assay implicated that PKC might play a role in regulating FMNL2 
but not mDia1 activity through phosphorylation. To further investigate the possible 
phosphorylation of FMNL2 by PKC, a point mutation of the Ser residue into Ala 
(S1072A) to destroy the phosphorylation was introduced to full length FMNL2. FMNL2 
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and the S1072A mutant were transiently expressed in cells and immunoprecipitated. A 
commercially available antibody, which identifies phospho-Ser PKC substrates, was used 
to detect whether FMNL2 was phosphorylated by PKC. Wild type FMNL2 could be 
phosphorylated with a strong increase under TPA treatment. Importantly, 
phosphorylation was diminished under BIM I treatment. The mutant S1072A could not 
be detected by the phospho-Ser PKC substrate antibody in all treatments, while mDia1 as 
a control showed no phosphorylation (Figure 17C).  
 
Figure 17. FMNL2 is phosphorylated by PKC at the residue Ser 1072. A. Schematic 
representation of FMNL2 protein and the amino acid sequences from different species are shown 
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for the DAD to C terminus regions. Hs: Homo sapiens; Mm: Mus musculus; Xt: Xenopus 
tropicalis; Dr: Danio rerio. Protein IDs from UniProt are listed. Yellow shadow shows the DAD 
domain. Basic residues are shown in red. The conserved Ser (S1072 in human) is labeled with 
asterisk and shown in green. Numbers indicate the residue boundaries of the domains. B. 
HEK293 cells expressing full length FMNL2 or mDia1 as indicated, together with MAL/SRF 
reporter 3DA.Luc and Renilla luciferase pRLTK. DMSO, 20 nM TPA or 2 µM BIM I + 200 nM 
TPA was incubated with the cells for 6 h. SRF activity was measured 24 h after transfection. 
Error bar: + s.e.m. (n=3), p<0.001. C. Flag-FMNL2, the phospho-deficient mutant Flag-FMNL2-
S1072A or Flag-mDia1 was expressed in HEK293 cells and immunoprecipitated after DMSO, 
TPA (20 nM) or BIM I (2 µM) treatments for 30 min. An antibody specifically recognizing 
phospho-Ser PKC substrate (α-pS-PKC substrate) was used to detect the phosphorylated proteins. 
D. Titration of TPA stimulated FMNL2 phosphorylation by PKC. The amount of TPA (nM) used 
in cell treatments is indicated. myc-FMNL2 was immunoprecipitated after 0 - 20 nM TPA 
treatments for 30 min. Phosphorylated FMNL2 was detected by α-pS-PKC substrate. E. Flag-
FMNL2-FH1-CT (WT), Flag-FMNL2-FH1-CT-S1072A (S1072A) or Flag-FMNL2-FH1-CT-
S1072E (S1072E) was immunoprecipitated after DMSO or TPA (20 nM) treatments for 30 min. 
Phosphorylated FMNL2 was detected by α-pS-PKC substrate. F. myc-FMNL2, FMNL2-myc or 
FMNL2-S1072A-myc was immunoprecipitated after DMSO, TPA (20 nM) or BIM I treatments 
for 30 min. Phosphorylated FMNL2 was detected by α-pS-PKC substrate. Numbers indicate 
molecular weight (kD). 
 
Figure 18. Phosphorylation of FMNL2 by PKC is enhanced by RhoC. A. FMNL2 was co-
expressed with or without C3 co-enzyme in HEK293 cells. myc-FMNL2 was immunoprecipitated 
after DMSO, TPA (5 nM) or BIM I (2 µM) treatments for 30 min. Phosphorylated FMNL2 was 
detected by phospho-Ser PKC substrate antibody. B. FMNL2 and HA-RhoCV14 were expressed. 
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myc-FMNL2 was immunoprecipitated after DMSO, TPA (20 nM) or BIM I (2 µM) treatments 
for 30 min. Phosphorylated FMNL2 and bound HA-RhoCV14 were detected. Numbers indicate 
molecular weight (kD). 
Moreover, FMNL2 phosphorylation could be induced in a dosage-dependent manner by 
TPA, and 5 nM was sufficient to show a distinguishing band in the immunoprecipitation 
(Figure 17D). A phospho-mimetic mutation was also introduced into FMNL2-FH1-CT 
(Ser 1072 mutated into Glu, S1072E) apart from the phospho-deficient mutantion 
S1072A. The wild type C-terminal half of FMNL2 was also phosphorylated while both 
S1072A and S1072E mutations in the C-terminal half were not (Figure 17E). It was 
reported that FMNL2 was N-myristoylated and this modification could localize FMNL2 
to the lamellipodia protrusions. N-terminal fusion of an epitope to FMNL2 would disrupt 
the co-translational myristoylation and the subcellular localization (Block et al., 2012). 
However, both N- and C- terminal tagged FMNL2 could be phosphorylated as shown in 
Figure 17F, suggesting that the epitope fusion did not affect the detection of 
phosphorylation.  
4.2.2	  Phosphorylation	  of	  FMNL2	  by	  PKC	  is	  enhanced	  by	  RhoC	  
Since FMNL2 was previously shown to be a RhoC effector (Figure 16), I assessed 
whether RhoC influences FMNL2 phosphorylation by PKC. First, C3 transferase was co-
expressed with FMNL2 and treated with DMSO, TPA or BIM I. Although 5 nM TPA 
was sufficient to induce phosphorylation of FMNL2 by PKC, no phosphorylation could 
be detected in the presence of C3 (Figure 18A) implying a role of Rho GTPase in the 
proper phosphorylation of FMNL2 by PKC. When constitutively active RhoC V14 was 
co-expressed with FMNL2, it was intriguing to see that phosphorylation was significantly 
enhanced even under an inhibitory condition of BIM I treatment (Figure 18B). 
Interestingly, in the immunoprecipitation, RhoC V14 was shown to interact with full 
length FMNL2 (Figure 18B), recapitulating the previous finding that FMNL2 specifically 
interacts with RhoC (Kitzing et al., 2010). In conlusion, FMNL2 harbors a 
phosphorylation site, Ser 1072, which can be phosphorylated by PKC but not ROCK. 
This phosphorylation is enhanced in the presence of RhoC probably due to the roles of 
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RhoC in releasing the autoinhibitory conformation of FMNL2 and localizing FMNL2 to 
the plasma membrane or possibly other membrane structures of the cells. 
4.3	  FMNL2	  is	  specifically	  phosphorylated	  by	  PKCα	  in	  cells	  
The protein kinase C family is composed of ten highly homologous isozymes, which can 
be classified into three groups: classical PKCs (cPKCs: PKCα, PKCβI, PKCβII, PKCγ), 
novel PKCs (nPKCs: PKCδ, PKCε, PKCη, PKCθ) and atypical PKCs (aPKCs: PKCζ, 
PKCλ/ι). Individual PKC isozymes have distinct roles in proliferation, apoptosis, cell 
survival and migration in a cell-type dependent manner (Griner and Kazanietz, 2007). In 
order to find out which isozyme is able to phosphorylate FMNL2, in vitro kinase assays 
were performed. Both wild type and S1072A mutant peptides ranging from the DAD 
domain to the C-terminus of FMNL2 (aa 959-1092) were subjected to the kinase 
reactions. Among the ten human PKC isozymes, PKCα, PKCβI, PKCβII, PKCδ and 
PKCε could phosphorylate FMNL2 in vitro whereas none of the PKCs could 
phosphorylate the S1072A mutant (Figure 19A). When incubated with the kinase 
inhibitor staurosporine, wild type peptide was not phosphorylated by PKCα (Figure 19A). 
It is known that PKC substrate specificity is less specific in vitro than in vivo. Therefore 
immunoprecipitations were conducted to uncover the specificity between the kinase and 
the substrate. PKCα, PKCβ, PKCδ and PKCε which showed activity toward FMNL2 
peptide in vitro, along with PKCζ as a control, were silenced respectively in cells 
overexpressing FMNL2. Only when PKCα was silenced in cells, the phosphorylation 
level of FMNL2 was dramatically reduced (Figure 19B) implicating that FMNL2 is 
specifically a substrate of PKCα. 
Gö6976, which specifically inhibits PKCα and PKCβI, was then used. Gö6976 reduced 
the phosphorylation of FMNL2 to the same extent as BIM I (Figure 20A). To test 
whether FMNL2 associates with PKCα, immunoprecipitations were performed under 
DMSO, TPA or BIM I treatments. When cells were treated with BIM I, a stronger 
interaction between FMNL2 and PKCα was detected (Figure 20B). Importantly, the 
dominant-negative form of PKCα inhibited FMNL2 phosphorylation as well as BIM I, 
while the wild type and constitutively active form of PKCα could increase the 
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phosphorylation the same as the TPA treatment (Figure 20C). Moreover, endogenous 
FMNL2 was immunoprecipitated from cells treated with BIM I or TPA. Phosphorylation 
of the endogenous FMNL2 could be detected when induced by TPA, suggesting that 
phosphorylation of FMNL2 by PKCα happens under physiological conditions (Figure 
20D). Taken together, FMNL2 is phosphorylated by PKCα, both in vitro and in vivo. 
PKCα associates with FMNL2 and the phosphorylation of FMNL2 is inhibited when 
PKCα is inactive. 
 
Figure 19. FMNL2 is specifically phosphorylated by PKCα in cells. A. In vitro kinase assays 
were performed using purified PKC isozymes and wild type (WT) or S1072A mutant FMNL2 C 
terminal fragments (GST-959-CT) as indicated. Autoradiography and coomassie blue stained gels 
are shown. 1 µM kinase inhibitor staurosporine was used when indicated. B. HEK293 cells were 
transfected with Flag-FMNL2 and siRNA against different PKC isoforms respectively. siPKCβ 
recognizes both PKCβI and PKCβII. Left: Flag-FMNL2 was immunoprecipitated and 
phosphorylated FMNL2 was detected by phospho-Ser PKC substrate antibody. Right: 
knockdown of different PKC isoforms are shown. Numbers indicate molecular weight (kD). 
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Figure 20. FMNL2 phosphorylation depends on PKCα activity. A. HEK293 cells expressing 
myc-FMNL2 were immunoprecipitated after DMSO, 20 nM TPA, 2 µM BIM treatment or 1 µM 
Gö6976 treatment. Phosphorylation was detected by phospho-Ser PKC substrate antibody. B. 
Immunoprecipitations of HEK293 cells expressing Flag-FMNL2 and GFP-PKCα after DMSO, 20 
nM TPA or 2 µM BIM treatments. Bound GFP-PKCα was detected by Western blotting. C. myc-
FMNL2 was immunoprecipitated in the presence or absence of GFP-PKCα wild type (WT), 
dominant-negative (DN) or constitutively active (CA). DMSO, 20 nM TPA or 2 µM BIM was 
added when indicated. Phosphorylation was detected. D. HeLa cells were treated with 2 µM BIM 
or 20 nM TPA for 30 min and immunoprecipitated with FMNL2 antibody. Endogenously 
phosphorylated FMNL2 was detected by phospho-Ser PKC substrate antibody. Numbers indicate 
molecular weight (kD). 
4.4	  FMNL2	  is	  internalized	  upon	  PKCα	  activation	  
4.4.1	  FMNL2	  is	  internalized	  upon	  PKCα	  activation	  by	  TPA	  
Classical PKCs and nPKCs, both containing a regulatory C1 domain with diacylglycerol 
(DAG) binding ability, are known to be translocated from the cytosol to membrane 
fractions when activated by DAG or phorbol esters (Kraft et al., 1982; Mochly-Rosen et 
al., 2012; Sakai et al., 1997). Only the fully translocated and activated PKCs have kinase 
activity towards the substrates. Since FMNL2 shows prominent plasma membrane 
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localization and is proved to be a substrate of PKCα, it is important to image the changes 
of FMNL2 and PKCα localization upon PKCα activation in living cells. Therefore, 
FMNL2-mCherry and GFP-PKCα were transiently expressed in HeLa cells. FMNL2 
showed intense fluorescence on the plasma membrane and some vesicular structures in 
the cytoplasm, while PKCα was homogenously distributing in the cytoplasm when 
inactive. Upon addition of TPA, PKCα rapidly translocated from the cytoplasm to the 
plasma membrane within 300 s. FMNL2 gradually disappeared from the cortical plasma 
membrane and appeared in the intracellular vesicular structures (Figure 21A). Changes of 
fluorescence intensity on the plasma membrane were quantified for both FMNL2 and 
PKCα. The fluorescence intensity of PKCα on the plasma membrane increased upon 
activation by TPA until it reached a peak at around 300 s. Concomitantly, FMNL2 was 
internalized and the plasma membrane fluorescence intensity dropped (Figure 21A).  
BIM I inhibitor was then used to test whether internalization of FMNL2 is a consequence 
of PKCα activation. Cells were pre-incubated with BIM I inhibitor for 30 min and 
imaging acquisition was started immediately after TPA was added. Translocation of 
PKCα happened similar to that of TPA treatment only (Figure 21B). BIM I is an ATP-
competitive inhibitor which binds the kinase domain (Grodsky et al., 2006), while TPA 
binds the regulatory domain (Steinberg, 2008). Hence, although PKCα was translocated, 
it could not phosphorylate the substrates for its ATP binding site was occupied by BIM I. 
Thus FMNL2 was not phosphorylated. The observation that FMNL2 kept the plasma 
membrane localization throughout the experiment suggests that FMNL2 internalization 
depends on PKCα activity (Figure 21B). Quantification confirmed that although PKCα 
translocated, FMNL2 exhibited no change of fluorescence intensity on the plasma 
membrane (Figure 21B). Of note, the vesicular-like structures in cells treated with BIM I 
came from the fluorescent signals of the BIM I compound.  
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Figure 21. FMNL2 changes localization from the plasma membrane to intracellular 
membrane structures upon PKCα activation by TPA. A. Upper: HeLa cells expressing 
FMNL2-mCherry and GFP-PKCα were imaged immediately after applying 200 nM TPA. 
Representative frames are shown at indicated time points. Lower: Quantification of fluorescence 
intensity changes on the plasma membrane for both the red and the green channel. Photo 
bleaching was corrected. Red: mCherry; Green: GFP. Scale bar: 10 µm. Error bar, +/- s.e.m of 11 
cells. B. Upper: HeLa cells expressing FMNL2-mCherry and GFP-PKCα were pre-treated with 2 
µM BIM for 30min. Images were acquired immediately after applying 200 nM TPA. 
Representative frames are shown at indicated time points. Lower: Quantification of fluorescence 
intensity changes on the plasma membrane. Photo bleaching was corrected. Scale bar: 10 µm. 
Error bar, +/- s.e.m of 4 cells.  
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Figure 22. Ser 1072 affects FMNL2 internalization rate. A. HeLa cells were transfected with 
control siRNA or FMNL2 siRNA labeled with AlexaFluor 555. siFMNL2 targeting 3’-UTR 
allowed FMNL2 wild type (FMNL2-GFP) or mutant (FMNL2-S1072A-GFP) DNA expression in 
the same cell. Left: Representative frames upon addition of 40 nM TPA are shown at indicated 
time points. Green: GFP; Red: AlexaFuor 555. Scale bar: 10 µm. Right: Western blots show 
knockdown of FMNL2. B. Quantification of fluorescence intensity changes on the plasma 
membrane when FMNL2-GFP or FMNL2-S1072A-GFP was expressed in control siRNA or 
FMNL2 siRNA transfected cells upon addition of 40 nM TPA. Photo bleaching was corrected. 
Error bar, +/- s.e.m of 7 (blue), 11 (red), 8 (green) and 9 (purple) cells respectively. C. FMNL2-
GFP-myc wild type, S1072A, or S1072E were expressed in HEK293 cells and 
immunoprecipitated. Endogenous and ectopic FMNL2 were detected by FMNL2 antibodies. 
Numbers indicate molecular weight (kD). 
Next, I examined whether the phospho-deficient mutant of FMNL2 (S1072A) could be 
internalized upon TPA stimulation. FMNL2-S1072A-mCherry displayed the same 
internalization pattern as wild type FMNL2 (data not shown). Since formins function as 
dimers and FMNL2 was reported to form homodimers (Vaillant et al., 2008), endogenous 
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FMNL2 was silenced with fluorescently labeled siRNA (siFMNL2-AlexaFluor 555) 
targeting 3’-UTR of FMNL2 gene, allowing for expression of exogenous FMNL2 
proteins. Upon TPA stimulation, both FMNL2-GFP and FMNL2-S1072A-GFP could be 
internalized in control siRNA transfected cells (Figure 22 A and B). FMNL2-GFP in 
FMNL2 siRNA transfected cells exhibited a decrease of fluorescence intensity on the 
plasma membrane the same as in the control siRNA condition. However, FMNL2-
S1072A-GFP in FMNL2 siRNA transfected cells showed a significantly slower 
internalization rate (Figure 22B). The difficulty to capture the discrepancy between the 
wild type and mutant proteins might come from the fact that the ectopic FMNL2 
dimerizes with the endogenous FMNL2. Indeed, when the overexpressed FMNL2 wild 
type or mutant was immunoprecipitated, endogenous FMNL2 could be detected (Figure 
22C). Therefore, the Ser 1072 residue contributes to FMNL2 internalization upon PKCα 
activation.  
4.4.2	  FMNL2	  internalization	  is	  reversible	  
PKC activation by DAG in cells is transient, while activation by TPA is permanent and 
irreversible (Griner and Kazanietz, 2007). Whether FMNL2 internalization is reversible 
like the PKC translocation is the next question to explore. The translocation of PKCγ 
induced by calcium was rapid and reversible when the cells were treated with the calcium 
ionophore A23187 (Sakai et al., 1997). Therefore, A23187 was tested with FMNL2 and 
PKCα. Upon addition of 8 µM A23187, PKCα translocated within 20 s and completed at 
75 s, while FMNL2 internalization followed. After 75 s, PKCα gradually translocated 
back from the plasma membrane to the cytoplasm probably due to the decrease of the 
intracellular calcium concentration. At 150 s, PKCα was completely cytoplasmic again, 
indicating the deactivation of the kinase. As a consequence, at 150 s, FMNL2 started to 
return to the plasma membrane, further suggesting that FMNL2 internalization is 
reversible and dependent on PKC activity (Figure 23A).  
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Figure 23. FMNL2 internalization is reversible and it localizes to the membrane structures 
throughout the process. A. HeLa cells expressing FMNL2-mCherry and GFP-PKCα were 
imaged immediately after applying 8 µM calcium ionophore A23187.  Representative images are 
shown at indicated time points. Scale bar: 10 µm. B. HEK293 cells over expressing FMNL2-GFP 
were fractionated by membrane flotation assays with or without 200 nM TPA treatment for 30 
min. Membrane and soluble fractions were analyzed by Western blotting using different 
antibodies as indicated. C. HeLa cells were fractionated by membrane flotation assay with or 
without 200 nM TPA treatment for 30 min. Membrane and soluble fractions were analyzed by 
Western blotting using different antibodies as indicated. Numbers indicate molecular weight 
(kD). D. HeLa cells were fractionated using discontinuous sucrose density gradient centrifugation 
with or without 200 nM TPA treatment for 30 min. All the fractions (F1 ~ F9) were analyzed by 
Western blotting using different antibodies as indicated. TfR: transferrin receptor; PM: plasma 
membrane; RE: recycling endosome; TGN: trans-Golgi network. 
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Figure 24. FMNL2 does not colocalize with Golgi network upon TPA. A. HeLa cells 
expressing FMNL2-mCherry (red) with or without 200 nM TPA for 10 min were stained for cis-
Golgi marker GM130 (green). White square of the TPA treated cell is enlarged to show details. B. 
HeLa cells expressing FMNL2-mCherry (red) and TGN38-YFP (green) with or without 200 nM 
TPA are shown. TGN38 is trans-Golgi marker. White square of the TPA treated cell is enlarged 
to show details. Scale bar: 10 µm. 
To further explore whether FMNL2 remains bound to the cellular membrane structures, 
membrane flotation assays were carried out. FMNL2-GFP was overexpressed and 
fractionated. As expected, PKCα as a soluble protein in the cytosol became membrane 
bound protein upon activation by TPA. However, FMNL2 remained as a membrane 
bound protein despite of the internalization observed, indicating that FMNL2 as a 
membrane bound protein is highly probably internalized via endocytic route. Endogenous 
FMNL2 behaved the same as overexpressed FMNL2 (Figure 23 B and C). To 
differentiate between individual cellular membrane systems, discontinuous sucrose 
density gradient was used to fractionate different membranes (Pan et al., 2012). 
Combining the membrane flotation results, FMNL2 primarily localized to the plasma 
membrane without TPA, while PKCα mainly localized in the cytoplasm. Transferrin 
receptor and α5 integrin distributed throughout the plasma membrane and recycling 
endosome membranes. When treated with TPA, PKCα translocated to membrane systems 
including the plasma membrane and Golgi membrane which was consistent with previous 
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reports (Goodnight et al., 1995; Griner and Kazanietz, 2007). However, FMNL2, 
transferrin receptor and α5 integrin did not show many changes upon TPA treatment, 
suggesting that within the time frame of the experiments FMNL2 did not go from the 
plasma membrane to the recycling endosomes or Golgi networks (Figure 23D). 
Meanwhile, immunostaining of FMNL2 and Golgi markers confirmed that FMNL2 did 
not colocalize with either cis- or trans-Golgi network before or after TPA treatment 
(Figure 24 A and B). 
4.4.3	  FMNL2	  is	  internalized	  through	  endocytosis	  
To identify the dynamics of FMNL2 after TPA treatment, endogenous or overexpressing 
subcellular markers were used to test whether they colocalize with FMNL2. Early 
endosome marker EEA1 (early endosome antigen 1) did not colocalize with FMNL2 
before or after TPA treatment (Figure 25A). When cells were loaded with fluorescently 
labeled transferrin showing the endocytic pathway from early endosomes to recycling 
endosomes, FMNL2 did not colocalize with transferrin (Figure 25B). However, in some 
of the cells, FMNL2 colocalized with the endosome markers Rab4, Rab5 and Rab7 to 
different extents after TPA treatment (Figure 25C). FMNL2 accumulated in the region 
where Lamp1 (lysosomal-associated membrane protein 1) localized after addition of TPA, 
but did not exhibit any distinct structure which resembled Lamp1 (Figure 25D). Finally, 
constitutively active RhoC V14 was co-expressed with FMNL2. Without TPA treatment, 
RhoC V14 localized to the plasma membrane and intracellular membrane compartments. 
FMNL2 colocalized with RhoC V14 at the plasma membrane. Upon TPA treatment, 
FMNL2 was internalized and it colocalized with RhoC V14 on the intracellular 
membrane compartments (Figure 25E) confirming the RhoC-FMNL2 interaction.  
In summary, FMNL2 follows an internalization route when PKCα is translocated and 
activated. Due to the dimerization with endogenous FMNL2, phospho-deficient mutant 
FMNL2-S1072A is internalized at a slower rate only when endogenous FMNL2 level is 
reduced, suggesting that the Ser residue plays a role in the kinetic process. Moreover, 
FMNL2 internalization is reversible. Deactivation of PKCα leads to the returning of 
FMNL2 to the plasma membrane. FMNL2 always associates with cell membrane 
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structures, but not with Golgi network, EEA1 or transferrin. However, in some cells, 
FMNL2 partially colocalizes with the ectopically expressed endosome markers Rab4, 
Rab5 and Rab7 indicating that FMNL2 might follow the endocytic pathway to be 
internalized.  
 
Figure 25. FMNL2 is internalized to intracellular membrane structures upon TPA. A. 
Representative images of FMNL2-mCherry (red) and EEA1 (green) in HeLa cells.	   B. 
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Representative images of FMNL2-mCherry (red) and transferrin (green) in HeLa cells. 
Fluorescently labeled transferrin were uptaken by HeLa cells for 10 min. C. Representative 
images of FMNL2-mCherry (red) and GFP-Rabs (green) in HeLa cells. Inserts show details of 
the colocalization. D. Representative images of FMNL2-GFP (green) and Lamp1 (red) in HeLa 
cells. White square of the TPA treated cell is enlarged to show details. E. Representative images 
of FMNL2-mCherry (red) and CFP-RhoC V14 (green) in HeLa cells. White square of the TPA 
treated cell is enlarged to show details. TPA treatment: 200 nM, 10min. Scale bars: 10 µm. 
4.5	  FMNL2	  is	  required	  for	  α5β1	  integrin	  internalization	  
4.5.1	  Knockdown	  of	  FMNL2	  reduces	  β1	  integrin	  internalization	  
A cell spot microarray screen (Arjonen et al., 2012; Rantala et al., 2011) of genes 
regulating β1 integrin endocytosis was conducted by Arjonen et al. of Turku Centre for 
Biotechnology, Finland, which revealed that among all the formins except for INF1, 
silencing of FMNL2 led to a dramatic decrease in β1 integrin endocytosis in both HeLa 
and MDA-MB-231 cells (Arjonen et al., unpublished data). Thereby, HeLa cell lines 
stably expressing shFMNL2 or control shRNA were made with nice reduction of 
endogenous FMNL2 (Figure 26A). Pouwels et al. of Turku Centre for Biotechnology, 
performed biotin-IP based β1 integrin endocytosis assay with the stable cell line and 
validated that loss of FMNL2 in cells led to a significant decrease of β1 integrin 
endocytosis at 15, 20 or 30 min time points (Figure 26A). To test whether FMNL2 
interacts with integrin cytoplasmic tail like other integrin interacting partners, biotin-
strepdavidin pull down assays were performed. Biotinylated cytoplasmic tail of α5 but 
not β1 integrin could interact with FMNL2 (Figure 26B). Since α5β1 integrin was known 
to function as heterodimers, cell surface levels of α5 or α5β1 integrin were measured with 
silenced FMNL2 in cells. Corresponding to the β1 integrin endocytosis results, loss of 
FMNL2 in HeLa cells led to an increased level of cell surface α5 or α5β1 integrin (Figure 
26C). Thus, FMNL2 interacts with the α5 integrin cytoplasmic tail and is required for 
α5β1 integrin internalization. 
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Figure 26. FMNL2 is required for α5β1 integrin internalization. A. Left: biotin-IP based β1 
integrin internalization assays show silencing of FMNL2 leading to less internalized β1 integrin 
in HeLa cells stably expressing control or FMNL2 shRNA. Error bars: +s.e.m (n=3), p<0.001. 
Time points indicate the time of the internalization. Right: Western blotting showing the 
knockdown efficiency of the stable cell line.  B. Biotin-strepdavidin pull down (Pd) of integrin 
cytoplasmic tails and FMNL2-myc from HEK293 cell extracts. C. Upper: Flow cytometry 
measurements of cell surface α5 or α5β1 integrin level while silencing FMNL2 in HeLa cells. 
Error bars: +s.e.m (n=3), two stars: p<0.001, one star: p<0.05.  Lower: Western blotting showing 
the knockdown efficiency. Numbers next to Western blots indicate the molecular weight of 
molecules. 
4.5.2	  FMNL2	  localizes	  to	  α5	  integrin	  positive	  vesicles	  
To further confirm that FMNL2 and α5 integrin interact in cells, immunoprecipitation 
was carried out. Indeed, α5 integrin could be detected when FMNL2 was 
immunoprecipitated from HEK293 cells transiently expressing both proteins (Figure 
27A). However, when α5 integrin and FMNL2 were co-expressed in HeLa cells, FMNL2 
was found mainly on plasma membrane while α5 integrin localized on plasma membrane, 
intracellular membrane compartments and vesicular structures (Figure 27A). It was 
previously reported that stimulation of PKCα activity induced β1 integrin internalization 
(Ng et al., 1999). FMNL2 was found to be internalized and it interacted with α5 integrin. 
Thus, the effects of TPA on FMNL2 and α5 integrin were examined. Upon TPA 
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treatment, FMNL2 started to be internalized, co-trafficking with α5 integrin vesicles and 
finally accumulated in the perinuclear membrane compartments where α5 integrin was 
also present (Figure 27A). Moreover, FMNL2 also colocalized with endogenous α5 
integrin (Figure 27B).   
 
Figure 27. FMNL2 localizes on α5 integrin positive vesicles upon TPA treatment. A. Left: 
immunoprecipitation showing FMNL2 interacting with α5 integrin in cells. Numbers indicate the 
molecular weights. Right: FMNL2-mCherry and α5 integrin-GFP were expressed in HeLa cells 
and 200 nM TPA was applied to cells at timepoint zero. Representative images of the live cell 
imaging are shown here. White square of is zoomed in to show details. B. FMNL2-mCherry and 
endogenous α5 integrin localization with or without 200 nM TPA treatment for 10 min. White 
box of the TPA treated cell is enlarged to show details. Scale bars: 10 µm. 
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4.5.3	  Effects	  of	  FMNL2	  mutants	  on	  α5β1	  integrin	  surface	  levels	  
To understand whether internalization of FMNL2 depends on its actin polymerization 
activity, mutations were made to disrupt FMNL2-actin interaction. It is known that an Ile 
residue in the FH2 domain is conserved among all formins and is essential for formins to 
bind barbed ends of actin filaments (Xu et al., 2004). In FMNL2, it is Ile 704 (I704). 
Thus I704 was mutated into Ala (I704A) in FMNL2. In addition, all the three FMNLs 
contain a WH2 domain between FH2 and DAD domains. In FMNL3, the C-terminal 
region containing the WH2 binds actin monomers and barbed ends (Heimsath and Higgs, 
2012). Therefore, by comparing the WH2 domain sequences of FMNLs, INF2, WASP 
and WAVE2, the two conserved residues Leu 1028 and Ile 1029 which are important for 
actin binding were also mutated into Ala in FMNL2. In total, this actin binding-deficient 
FMNL2 mutant was named ILI3A (I704A, L1028A and I1029A. Figure 28 A and B). 
Indeed, ILI3A mutant showed no activity in MAL/SRF luciferase reporter assays and 
when co-expressed with wild type FMNL2, ILI3A behaved as a dominant-negative 
mutant that inhibited FMNL2 activity on actin assembly (Figure 28B).  
To test whether the phospho-deficient, phospho-mimetic and actin binding-deficient 
mutants affect α5β1 integrin internalization, cell surface α5β1 integrin levels were 
measured in stable HeLa cell lines (Figure 28C). Silencing of FMNL2 led to a dramatic 
decrease in β1 integrin internalization and an increase in α5β1 integrin cell surface level 
(Figure 26 A and C). Expression of FMNL2 resulted in lower α5 or α5β1 integrin cell 
surface levels (Figure 28C). However, FMNL2-S1072A or FMNL2-S1072E expression 
in cells did not show any difference in comparison to the wild type. The actin binding-
deficient mutant of FMNL2 (ILI3A) also led to lower α5 or α5β1 integrin levels on the 
cell surface the same as wild type. Moreover, combined mutations (ILIS4A or ILI3ASE) 
affecting FMNL2 phosphorylation (S1072A or S1072E) and actin binding (ILI3A) were 
generated. Their effects on the α5β1 integrin cell surface levels were also not altered 
(Figure 28C). The similar effects of wild type and mutant FMNL2 on α5β1 integrin 
surface levels could be due to the dimerization between the endogenous FMNL2 and the 
ectopic FMNL2. 
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Figure 28. Effects of FMNL2 mutants on α5β1 integrin cell surface levels. A. The C-terminal 
sequences of FMNLs, INF2, WASP and WAVE2 showing the WH2 domains. Light orange 
shadow indicates the WH2 domain. Yellow shadow indicates the DAD domain. Numbers indicate 
the amino acids in the genes. Red letters show the conserved residues that are important for actin 
binding. Sequences are from UniProt. B. HEK293 cells expressing full length FMNL2-GFP (FL) 
or mutant as indicated, together with MAL/SRF reporter 3DA.Luc and Renilla luciferase pRLTK. 
Black triangle indicates the increasing amount of DNA transfected. SRF activity was measured 
24 h after transfection. Error bar: + s.e.m. (n=3). C. Flow cytometry measurements of cell surface 
α5 or α5β1 integrin levels from stable HeLa cell lines as indicated. Error bars: +s.e.m (n=3), two 
stars: p<0.001, one star: p<0.05. Student t-tests were always performed between the control cells 
expressing GFP only and the cells expressing FMNL2 variants either for α5 or α5β1 integrin, 
respectively.  
4.6.	  Release	  of	  FMNL2	  autoinhibition	  by	  PKCα	  phosphorylation	  promotes	  
rounded	  cell	  invasion	  in	  3D	  
As shown in Figure 16B, autoinhibition of FMNL2 could be released by constitutively 
active RhoC V14. Whether phosphorylation of FMNL2 by PKCα plays a role in the 
autoregulation was then assessed with MAL/SRF luciferase reporter assay. N- or C-
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terminal tagged FMNL2, FMNL2-S1072A and FMNL2-S1072E were expressed in cells. 
Wild type FMNL2 showed a bit higher activity compared to control, while FMNL2-
S1072A behaved almost the same as the control. Interestingly, FMNL2-S1072E which 
mimics the phosphorylated version of FMNL2 exhibited a much higher activity 
compared to the other two (Figure 29 A and B). Moreover, FMNL2-FH3 which includes 
the DID domain interacted with FMNL2-FH1-CT which includes the DAD domain. The 
interaction was stronger in cells treated with DMSO or BIM I than in cells treated with 
TPA (Figure 29C). TPA induces FMNL2-FH1-CT phosphorylation on Ser 1072 by PKC 
(Figure 17E). The data suggest that phosphorylation of S1072 disrupts FMNL2 DID-
DAD interaction and thus autoinhibition.  
Knockdown of FMNL2 significantly reduced rounded cell invasion in transwell invasion 
assays using Matrigel (Kitzing et al., 2010). Amoeboid or rounded single cell invasion 
requires low integrin mediated adhesion and high Rho-mediated cortical actomyosin 
contractility (Hegerfeldt et al., 2002; Sanz-Moreno et al., 2008). As shown in Figure 26C, 
knockdown of FMNL2 led to an increased cell surface α5 or α5β1 integrin. To test the 
actomyosin contractility, phosphorylation of myosin II light chain (p-MLC) was 
examined (Olson and Sahai, 2008; Somlyo and Somlyo, 2000) in cells which FMNL2 
was silenced. Reduced FMNL2 level led to reduced p-MLC, especially when cells were 
starved and stimulated with serum (Figure 29D), indicating a possible feedback loop 
among FMNL2-Rho GTPase-ROCK, similar to mDia1 (Kitzing et al., 2007). Similar 
phenomena were observed in both HeLa and MDA-MB-435 cells (data not shown for 
MDA-MB-435 cells). Furthermore, when FMNL2, FMNL2-S1072A or FMNL2-S1072E 
was stably expressed in A375M2 melanoma cells which employ round morphology 
during invasion (Sahai and Marshall, 2003), all induced cell invasion into 3D Matrigel 
but to different extents (Figure 29E). The phospho-mimetic mutant S1072E induced 
A375M2 invasion more than two folds compared to the control indicating that the partial 
release of the autoinhibition promotes actin turnover so that cells might invade faster. 
Wild type FMNL2 induced invasion better than the phospho-deficient mutant S1072A, 
suggesting that wild type FMNL2 can be phosphorylated so that it is more active than 
S1072A mutant. In conclusion, phosphorylation of FMNL2 by PKC partially releases its 
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autoinhibition. FMNL2 is required for cells to keep proper levels of cell surface integrin 
and actomyosin contractility, which is important for rounded cell invasion. The phospho-
mimetic mutant S1072E driving A375M2 rounded cell invasion more than the wild type 
or the phospho-deficient mutant, is probably due to the higher actin assembly activity of 
this mutant.  
 
Figure 29. Effects of FMNL2 phosphorylation on rounded cell invasion in 3D. A. HEK293 
cells were transfected with myc-FMNL2, FMNL2-S1072A or FMNL2-S1072E, together with 
MAL/SRF reporter 3DA.Luc and Renilla luciferase pRLTK. SRF activity was measured 24 h 
after transfection. Error bar: + s.e.m. (n=3). B. FMNL2, FMNL2-S1072A or FMNL2-S1072E-
GFP-myc was expressed in the same assay as in A. Error bar: + s.e.m. (n=3). C. 
Immunoprecipitations of HEK293 cells expressing Flag-FMNL2-FH1-CT and myc-FMNL2-FH3 
after DMSO, 200 nM TPA or 2 µM BIM treatment. D. FMNL2 were silenced by two different 
siRNAs in HeLa cells. After 72 hours, cells were starved for 3 hours and stimulated with 20% 
fetal bovine serum for 10 min. Phospho-myosin light chain (p-MLC), MLC and FMNL2 were 
detected in Western blotting. Numbers indicate molecular weight (kD). E. Left: Representative 
images of 3D Matrigel invasion using A375M2 cells stably expressing GFP or GFP-tagged 
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proteins after doxycycline (dox) induction. Lower panel shows the z-projection. Dashed line 
indicates the membrane of the insert. Green: GFP; Red: rhodamine-phalloidin. Scale bar: 20 µm. 
Right: Invasion of A375M2 cells stably expressing GFP, FMNL2-GFP, FMNL2-S1072A-GFP 
and FMNL2-S1072E-GFP are shown. Percentage of invaded cell over the total cell number was 
quantified and normalized between dox-induced and non-induced cells. Error bar: + s.e.m. (n=3); 
two stars: p < 0.001; one star: p < 0.05. 
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5	  Discussion	  
Cell motility is mainly driven by the dynamic reorganization of the actin cytoskeleton 
(Pollard and Borisy, 2003). The nucleation promoting factors of the Arp2/3 complex, and 
other actin regulating proteins such as Rho GTPases, cofilin, LIM kinase have been 
extensively studied in cancer models (Bravo-Cordero et al., 2011; Ellenbroek and 
Collard, 2007; Nürnberg et al., 2011; Olson and Sahai, 2008; Wang et al., 2007). Formins, 
as the largest family of actin nucleators and the largest group of Rho GTPase effectors, 
are emerging to be involved in cancer cell adhesion, migration and invasion. FMNL2 is 
widely expressed in human tissues and is upregulated in colorectal cancer (Zhu et al., 
2011, 2008). In addition, it is required for rounded cell invasion in 3D downstream of 
RhoC (Kitzing et al., 2010). Here, I described a novel regulatory mechanism of FMNL2 
through phosphorylation by protein kinase C, which is involved in cancer cell invasion.  
5.1	  Effects	  of	  FMNL2	  on	  actin	  assembly	  
Although diverse formins employ a common mechanism to assemble actin filaments, 
there are substantial differences in the kinetic reaction (Kovar, 2006; Pollard, 2007). In 
the FMNL subfamily, FMNL1 and FMNL3 show low actin polymerization activity in 
vitro (Harris, 2006; Heimsath and Higgs, 2012). However, FMNL2 inhibits actin 
polymerization in a concentration-dependent manner. This was confirmed in another 
study (Block et al., 2012). This inhibitory effect of FMNL2-FH1-CT on actin 
polymerization also affects the polymerizing ability of mDia1, implicating a strong 
interaction between FMNL2 and the barbed ends of actin filaments. Thus, FMNL2 may 
remain binding to the barbed ends replacing mDia1.  
Although FMNL2 exhibits an inhibitory effect on actin polymerization in vitro, there is 
no evidence for cellular FMNL2 to inhibit actin assembly. For example, FMNL2-FH1-
CT induces stress fiber formation in cells. Thus, it is questionable how useful the in vitro 
assay is to study FMNL2 functions. The in vitro assay may lack important factors which 
are necessary for the proteins to function properly in cells. Thus, the lack of actin 
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polymerization activity in vitro does not exclude that FMNL2 can polymerize actin under 
physiological conditions. It is possible that FMNL2 needs additional factors to adopt a 
proper conformation for actin polymerization in cells.  
5.2	  Nuclear	  localization	  of	  FMNL2	  C-­‐terminus	  
The C-terminus of FMNL2 (FMNL2-FH1-CT) shows accumulation in the cell nucleus. 
Studies on deletion mutants indicate that a possible nuclear localization sequence (NLS) 
lies within the WH2 domain of FMNL2. Why should formins be targeted into the nucleus? 
A recent study showed that serum stimulation could induce nuclear actin polymerization, 
which depends on the activation of endogenous mDia in the nucleus. The actin assembly 
activity of mDia in the nucleus also leads to accumulation of MAL in the nucleus 
(Baarlink et al., 2013). FMNL2 harbors a putative NLS and endogenous FMNL2 seems 
to have a nuclear distribution in cells (Gardberg et al., 2010). Whether autoinhibition 
masks the NLS of FMNL2 and whether its activation is related to the nuclear localization 
need to be studied.  
5.3	  Membrane	  localization	  of	  FMNL2	  
Endogenous FMNL2 was reported to localize diffusely in the cytoplasm and the peri-
nuclear region (Gardberg et al., 2010). However, these results should be interpreted with 
caution since the FMNL2 antibody was reported to recognize both FMNL2 and FMNL3 
(Block et al., 2012). Here, it is demonstrated that ectopically expressed FMNL2 localizes 
to the plasma membrane and intracellular membranes. Although Rho GTPases play a 
central role in recruiting formins to cellular membranes, recent studies suggest that 
additional factors help to drive membrane localization and activation of certain formins 
(Brandt et al., 2007; Chhabra et al., 2009; Copeland et al., 2007; Seth et al., 2006). 
Indeed, RhoC is found to be important for the plasma membrane localization of FMNL2. 
Moreover, FMNL2 was reported to be N-myristoylated. Mutation of the myristoylation 
site prevented FMNL2 from localizing to lamellipodia (Block et al., 2012). A similar 
phenomenon has been observed in this work. Loss of myristoylation leads to the loss of 
plasma membrane localization of full length FMNL2, whereas the isolated N-terminus 
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containing the Rho GTPase binding domain of FMNL2 can still localize to the plasma 
membrane even in the absence of myristoylation (data not shown). Thus, a potential 
model of FMNL2 subcellular localization could be that myristoylation ensures that 
FMNL2 is tethered to cellular membranes in its autoinhibited conformation, while RhoC 
regulates the activity of FMNL2 and modulates the type of membrane to which FMNL2 
is bound. It is not clear whether FMNL2 is first released from autoinhibition and 
recruited to the plasma membrane or it is activated at the plasma membrane after the 
recruitment. In this regard, the regulation of FMNL2 localization may need additional 
factors. Although useful information can be obtained by observing the localization 
behavior of the overexpression of proteins in cells, better antibodies are needed to 
reliably address the localization and function of endogenous FMNL2 under different 
conditions. 
5.4	  Phosphorylation	  of	  FMNL2	  
5.4.1	  FMNL2	  is	  post-­‐translationally	  phosphorylated	  
Emerging evidences implicate that additional factors, other than Rho GTPases, are 
involved in the activation of formins. The activity of a number of formins is subject to 
phosphorylation (Hannemann et al., 2008; Matheos et al., 2004; Takeya et al., 2008; 
Wang et al., 2009). In a search for additional factors regulating its activity, FMNL2 was 
found to be phosphorylated by PKC at Ser 1072. Among all the PKC isozymes, FMNL2 
could be phosphorylated by several PKCs in the in vitro kinase assays, while it appears to 
be specifically phosphorylated by PKCα in cells. This discrepancy of in vitro and in vivo 
results may come from the reduced specificity between the kinases and the substrates in 
vitro, and the lack of regulatory factors in the in vitro system. The specificity of FMNL2 
phosphorylation by PKCα indicates that there might be a specific function regulated by 
PKCα activation. In addition, the interaction between FMNL2 and PKCα is stronger in 
cells treated by BIM I inhibitor. Since the enzymatic reaction between kinases and their 
substrates are highly transient and dynamic, it is possible that BIM I as an ATP-
competitive inhibitor locks the kinase domain of PKCα at a conformation favorable for 
FMNL2 binding.  
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Like other prototypic formins, FMNL2 autoinhibition is mediated by DID-DAD 
interaction (Kitzing et al., 2010; Vaillant et al., 2008). The Ser 1072 is located in close 
vicinity to the DAD domain, which led to the hypothesis that phosphorylation on this 
residue might affect the DID-DAD interaction of FMNL2. Indeed, the DID-DAD 
interaction is weaker when Ser 1072 is phosphorylated. Thus, the phosphorylation of 
FMNL2 by PKC may substantially contribute to FMNL2 autoinhibition. Moreover, 
phosphorylation of FMNL2 can be enhanced by RhoC. Thus RhoC releases the 
autoinhibition of FMNL2 and enhances FMNL2 phosphorylation by PKC, whereas this 
phosphorylation can also release FMNL2 autoinhibition. How the three events are 
interconnected and which one is the initiating factor remain elusive. Active PKC 
localizes to the plasma membrane. It is observed that FMNL2 colocalizes with active 
RhoC on the plasma membrane and intracellular membrane structures. Hence it is likely 
that through binding to FMNL2 GBD, RhoC recruits or facilitates FMNL2 localization in 
a close vicinity to PKC. In addition, RhoC binding can release FMNL2 into a 
conformation that is favorable for kinase-substrate reaction, which ultimately enhances 
the phosphorylation of FMNL2. Phosphorylation may further stabilize or reinforce the 
active conformation of FMNL2.  
Taken together, FMNL2 is not restricted to the regulation of Rho GTPase only, but 
become integrated into a signaling network which also involves PKC regulation and 
function. How RhoC and PKC coordinate in regulating FMNL2 activity and function 
opens an interesting field for future studies.  
5.4.2	  Internalization	  of	  FMNL2	  upon	  PKCα	  activation	  
Translocation from the cytoplasm to the plasma membrane upon activation is a unique 
property of the classical and novel PKCs (Sakai et al., 1997). It is intriguing that FMNL2 
is gradually internalized upon PKCα translocation and activation. However, the phospho-
deficient mutant (S1072A) of FMNL2 is also internalized as the wild type when 
overexpressed in cells (data not shown). One possible explanation is that overexpressed 
FMNL2 dimerizes with endogenous FMNL2 so that the mutant can also be internalized 
upon PKCα activation. Although internalization is not inhibited in an endogenous 
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FMNL2 reduced background, the phospho-deficient mutant shows a slower 
internalization rate. Hence, the Ser 1072 residue contributes to the internalization of 
FMNL2. The internalization might need the phosphorylation of other unknown residues 
on FMNL2. Although five more residues were tested according to consensus sequence 
scanning, none were responsible for this process. PKCα may also activate additional 
signals or factors, which regulate FMNL2 internalization.  
Phosphorylation of FMNL2 can release its autoinhibition. It was thus speculated that 
activated FMNL2 might locally initiate actin polymerization that is required for its 
internalization. A mutant FMNL2 defective in actin binding (FMNL2-ILI3A) could be 
internalized similarly as the wild type (data not shown). Thus it is unlikely that the actin 
assembly activity of FMNL2 is required for this process. Moreover, it has been reported 
that FMNL2 appears to activate PI3K, PKB/Akt, and MAPK signaling pathways (Liang 
et al., 2013). It is possible that FMNL2 may change the lipid composition of membranes 
which might be required for its internalization. 
Biochemical studies have shown that both endogenous and overexpressed FMNL2 are 
anchored to the cell membrane structures. The observation of FMNL2 redistribution from 
the plasma membrane to the intracellular membrane structures is most likely through 
membrane internalization. In other words, FMNL2 may follow endocytic route to 
accomplish internalization. Among the intracellular markers tested, FMNL2 has been 
found on Rab4, Rab5 or Rab7 positive endosomes pointing towards the fact that FMNL2 
may be endocytosed upon activation of PKCα. It remains unclear whether FMNL2 is 
involved in endosome motility or cargo transport. 
The application of the calcium ionophore, A23187, provides the evidence that FMNL2 
internalization is reversible as well as PKCα translocation and activation. PKCα is 
rapidly translocated by calcium that is brought into the cells by A23187. It is known that 
intracellular calcium concentration is tightly controlled. Thus it is likely that the high 
calcium concentration is reduced rapidly to a low level by the cells. Accordingly, PKCα 
is deactivated and translocated back to the cytosol gradually. Following PKCα 
deactivation, the internalized FMNL2 returns to the plasma membrane. Thus, FMNL2 
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internalization is reversible. The reversibility of the internalization of FMNL2 can be 
utilized by the cells to respond to extracellular cues and to rapidly transduce and switch 
off signals in time. 
5.5	  The	  relationship	  between	  FMNL2	  and	  β1	  integrin	  
PKCα is known to control the intracellular trafficking of integrin heterodimers via a 
direct interaction with β1 integrin (Ng et al., 1999; Parsons et al., 2002). FMNL2 was 
identified to be required for β1 integrin internalization (Arjonen et al., Turku centre for 
Biotechnology, unpublished data). It is consistent with the finding that FMNL2 appears 
on the endosome vesicles. Silencing of FMNL2 leads to an increased cell surface α5β1 
integrin level most likely due to the reduced internalization of β1 integrin. FMNL2 
interacts with the cytoplasmic tail of α5 integrin but not β1, indicating an indirect effect 
on β1 integrin through α5 integrin binding. Consistent with that, FMNL2 exhibits 
colocalization with α5 integrin positive vesicles.  
How could FMNL2 regulate the internalization of α5β1 integrin? It is known that formins 
regulate actin dynamics. Actin filament assembly can generate mechanical forces to 
induce membrane invagination and contraction (Kaksonen et al., 2006). Wild type 
FMNL2 negatively affects cell surface α5β1 integrin levels, implicating a role in 
regulating α5β1 integrin turnover. However, the ILI3A mutant defective in actin binding 
shows no differences on α5β1 integrin surface levels in comparison to the wild type. This 
mutant also exhibits colocalization with α5 integrin vesicles (data not shown). Thus, the 
role of FMNL2 in regulating α5β1 integrin internalization appears to be independent on 
FMNL2-mediated actin polymerization. Additionally, FMNL2 is found to interact with 
the nucleation promoting factor WASH that promotes Arp2/3 mediated branching 
(personal communication with Zech, Beatson Institute). WASH mediated actin 
polymerization is reported to be required for α5β1 integrin recycling (Zech et al., 2011). 
Hence, it is possible that FMNL2 acts as a bridge between α5β1 integrin and the actin 
assembly machinery. Another possibility is that the role of FMNL2 in α5β1 integrin 
internalization is not related to actin assembly at all. It might be that FMNL2 behaves as 
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a recruiting factor or a scaffolding protein to collect and transduce the signals to 
downstream factors in the endocytic pathway.   
The contribution of PKCα regulated FMNL2 activity to PKCα regulated β1 integrin 
trafficking is unclear. The internalization of α5β1 integrin mediated by the phospho-
mutants in an endogenous FMNL2 reduced background needs to be studied. It may also 
be necessary to compare the internalization rates of the mutant and the wild type FMNL2. 
So far, it is known that PKCα regulates β1 integrin trafficking, PKCα phosphorylates 
FMNL2 and PKCα activation leads to FMNL2 internalization. All the three signals may 
converge on FMNL2 to regulate α5β1 integrin internalization necessary for related 
cellular functions.  
5.6	  FMNL2	  in	  cancer	  cell	  invasion	  
Many actin regulators, including FMNL2, are shown to be upregulated in cancer 
progression (Nürnberg et al., 2011; Wang et al., 2004; Zhu et al., 2008). Although 
FMNL2 seems to be a poor actin nucleator in vitro, it has a role in actin turnover in cells 
(Kitzing et al., 2010). FMNL2 activity is regulated by phosphorylation. Consistently, the 
phospho-mimetic mutant of FMNL2 drives the invasion of A375M2 melanoma cells into 
3D Matrigel to a significantly higher degree than the phospho-deficient mutant. Thus, the 
driving force of promoting invasion in 3D may arise from the actin assembly activity of 
FMNL2.  
Rounded cell invasion requires low surface integrin level and high cortical actomyosin 
contractility (Hegerfeldt et al., 2002; Sanz-Moreno et al., 2008). FMNL2 negatively 
regulates β1 integrin surface level. Reduced FMNL2 in cells leads to a reduced level of p-
MLC, a marker of actomyosin contractility. Thus, FMNL2 affects three factors: actin 
polymerization, β1 integrin surface level and actomyosin contractility, which are all 
crucial for cancer cell invasion. These functions of FMNL2 might be regulated and 
connected by PKCα. The phosphorylation by PKCα activates FMNL2, which may 
regulate actin assembly. At the same time, PKCα activation results in FMNL2 
internalization which may be needed for β1 integrin turnover. However, the effect of 
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FMNL2 phosphorylation on p-MLC level remains elusive. How the three functions 
coordinate with each other and whether one of the functions is more important are 
unknown. Nevertheless, these functions could all affect the invasiveness of cancer cells. 
The important effects of FMNL2 in actin polymerization, β1 integrin surface level and 
actomyosin contractility make it an interesting candidate for cancer therapy. However, 
these effects also indicate that there might exist essential cellular functions of FMNL2 
which could restrain the effectiveness of anti-cancer drugs. 
5.7	  Conclusion	  
The work presented herein focuses on the regulation of FMNL2 and its role in cancer cell 
invasion. A novel mechanism of FMNL2 regulation was identified, which involves post-
translational modification of FMNL2 by PKCα at Ser 1072. Phosphorylation leads to a 
partial release of FMNL2 autoinhibition and accelerates cancer cell invasion in 3D matrix. 
Upon PKCα activation, FMNL2 is internalized through endocytosis providing a platform 
for spatiotemporal regulation of actin assembly. Phosphorylation of Ser 1072 affects the 
internalization rate of FMNL2. Internalized FMNL2 localizes to the α5 integrin positive 
vesicles. FMNL2 negatively affects cell surface α5β1 integrin levels (Figure 30). Hence, 
phosphorylation plays a role in FMNL2 activation and localization, which may exert 
functions in actin assembly and integrin trafficking. In addition, FMNL2 controls the p-
MLC level. Taken together, these factors may act in concert to explain the invasive 
capacity of the deregulated FMNL2. Through phosphorylation, FMNL2 is integrated into 
a signaling network which involves not only the regulation of Rho GTPase but also the 
regulation and function of PKC. This integration may account for the important functions 
of FMNL2 in regulating cell motility and also make FMNL2 an interesting candidate as 
an anti-invasive target for cancer therapy. 
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Figure 30. Schematic model of this work. Extracellular signals stimulate receptors which in 
turn activate phospholipase C (PLC). PLC cleaves phosphatidylinositol-4, 5-biphosphate (PIP2) 
into diacylglycerol (DAG) and inositol triphosphate (IP3). IP3 releases calcium from endoplasmic 
reticulum. Calcium binds protein kinase C (PKC) to pre-target PKC to membranes. Upon DAG 
binding, PKC undergoes a conformational change to be fully activated. FMNL2 is then 
phosphorylated by PKC and partially releases its autoinhibition. By regulating α5β1 integrin 
internalization through unknown mechanisms, FMNL2 promotes cancer cell invasion.  
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7	  Abbreviations	  
2D 2-dimensional 
3D 3-dimensional 
ADP Adenosine diphosphate 
Arp2/3 actin-related proteins 2/3 
ATP Adenosine-5´-triphosphate 
BIM I Bisindolylmaleimide I 
Cobl Cordon-bleu 
DAAM1 Disheveled-associated activator of morphogenesis 1 
DAAM2 Disheveled-associated activator of morphogenesis 2 
DAD Diaphanous autoregulatory domain 
DAG diacylglycerol 
Dia1 Diaphanous 1 
Dia2 Diaphanous 2 
Dia3 Diaphanous 3 
DID Diaphanous inhibitory domain 
DRF Diaphanous-related formin 
ECM Extracellular matrix 
EMT Epithelial to mesenchymal transition 
F-actin filamentous actin 
FH1/2/3 Formin homology 1/2/3 domain 
FHOD1 Formin homology domain-containing protein 1 
FHOD3 Formin homology domain-containing protein 3 
FMN1 Formin 1 
FMN2 Formin 2 
FMNL1 Formin-like 1 
FMNL2 Formin-like 2 
FMNL3 Formin-like 3 
G-actin globular actin 
7. Abbreviations	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GBD GTPase-binding domain 
INF1 Inverted formin 1 
INF2 Inverted formin 2 
IP3 inositol triphosphate 
JMY junction-mediating regulatory protein 
kD kilo Dalton 
Lmod Leiomodin 
mDia1 mouse Diaphanous 1 
MAL Megakaryocytic acute leukemia 
MLC myosin light chain 
MMP Matrix metalloproteinase 
NPF Nucleation promoting factor 
N-WASP neuronal-WASP 
PIP2 phosphatidylinositol-4, 5-biphosphate 
PIP3 phosphatidylinositol-3, 4, 5-triphosphate 
PKC Protein kinase C 
ROCK Rho-associated coiled-coil protein kinase 
SRF Serum response factor 
TPA 12-O-tetradecanoylphorbol-13-acetate 
WASH WASP and SCAR homologue 
WASP Wiskott-Aldrich syndrome protein 
WAVE WASP-family verprolin homologue 
WH2 domain WASP homology domain-2 
WHAMM WASP homologue associated with actin, membranes and 
microtubules 
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